

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 721 346 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
10.06.1998 Bulletin 1998/24

(21) Application number: 94926677.9

(22) Date of filing: 02.09.1994

(51) Int. Cl.⁶: **A61K 39/395**, A61K 38/17,
A61K 35/14, A61K 35/28
// (A61K39/395, 35:14),
(A61K39/395, 35:28),
(A61K38/17, 35:14)

(86) International application number:
PCT/US94/09953

(87) International publication number:
WO 95/06481 (09.03.1995 Gazette 1995/11)

(54) METHODS FOR INDUCING ANTIGEN-SPECIFIC T CELL TOLERANCE

VERFAHREN ZUR ANREGUNG ANTIGENSPEZIFISCHER T-ZELLTOLERANZ

PROCEDES PERMETTANT D'INDUIRE LA TOLERANCE DES CELLULES T A SPECIFICITE
ANTIGENIQUE

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

(30) Priority: 02.09.1993 US 116255
25.04.1994 US 232929

(43) Date of publication of application:
17.07.1996 Bulletin 1996/29

(73) Proprietor:
Trustees of Dartmouth College
Hanover, NH 03755 (US)

(72) Inventors:
• NOELLE, Randolph, J.
Cornish, NH 03745 (US)
• FOY, Teresa, M.
Lebanon, NH 03756 (US)
• DURIE, Fiona, H.
Seattle, WA 98107 (US)

(74) Representative:
Daniels, Jeffrey Nicholas et al
Page White & Farrer
54 Doughty Street
London WC1N 2LS (GB)

(56) References cited:
EP-A- 0 555 880

- THE JOURNAL OF IMMUNOLOGY, vol.151, no.4, 15 August 1993, BALTIMORE MD, USA pages 1777 - 1788 B. CASTLE ET AL. 'Regulation of expression of the ligand for CD40 on T helper lymphocytes.'
- JOURNAL OF CLINICAL IMMUNOLOGY, vol.13, no.3, May 1993, NEW YORK NY, USA pages 165 - 174 L. MARSHALL ET AL. 'The molecular basis for T cell help in humoral immunity: CD40 and its ligand, gp39.'
- IMMUNOLOGY TODAY, vol.13, no.11, November 1992, AMSTERDAM, THE NETHERLANDS pages 431 - 433 R. NOELLE ET AL. 'CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation.'
- THE JOURNAL OF EXPERIMENTAL MEDICINE, vol.178, no.5, 1 November 1993, NEW YORK NY, USA pages 1567 - 1575 T. FOY ET AL. 'In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**Background of the Invention**

To induce antigen-specific T cell activation and clonal expansion, two signals provided by antigen-presenting cells (APCs) must be delivered to the surface of resting T lymphocytes (Jenkins, M. and Schwartz, R. (1987) *J. Exp. Med.* 165, 302-319; Mueller, D.L., et al. (1990) *J. Immunol.* 144, 3701-3709; Williams, I.R. and Unanue, E.R. (1990) *J. Immunol.* 145, 85-93). The first signal, which confers specificity to the immune response, is mediated via the T cell receptor (TCR) following recognition of foreign antigenic peptide presented in the context of the major histocompatibility complex (MHC). The second signal, termed costimulation, induces T cells to proliferate and become functional (Schwartz, R.H. (1990) *Science* 248, 1349-1356). Costimulation is neither antigen-specific, nor MHC restricted and is thought to be provided by one or more distinct cell surface molecules expressed by APCs (Jenkins, M.K., et al. (1988) *J. Immunol.* 140, 3324-3330; Linsley, P.S., et al. (1991) *J. Exp. Med.* 173, 721-730; Gimmi, C.D., et al. (1991) *Proc. Natl. Acad. Sci. USA.* 88, 6575-6579; Young, J.W., et al. (1992) *J. Clin. Invest.* 90, 229-237; Koulouva, L., et al. (1991) *J. Exp. Med.* 173, 759-762; Reiser, H., et al. (1992) *Proc. Natl. Acad. Sci. USA.* 89, 271-275; van-Seventer, G.A., et al. (1990) *J. Immunol.* 144, 4579-4586; LaSalle, J.M., et al. (1991) *J. Immunol.* 147, 774-80; Dustin, M.I., et al. (1989) *J. Exp. Med.* 169, 503; Armitage, R.J., et al. (1992) *Nature* 357, 80-82; Liu, Y., et al. (1992) *J. Exp. Med.* 175, 437-445). One costimulatory pathway involved in T cell activation involves the molecule CD28 on the surface of T cells. This molecule can receive a costimulatory signal delivered by a ligand on B cells or other APCs. Ligands for CD28 include members of the B7 family of B lymphocyte activation antigens, such as B7-1 and/or B7-2 (Freedman, A.S. et al. (1987) *J. Immunol.* 137, 3260-3267; Freeman, G.J. et al. (1989) *J. Immunol.* 143, 2714-2722; Freeman, G.J. et al. (1991) *J. Exp. Med.* 174, 625-631; Freeman, G.J. et al. (1993) *Science* 262, 909-911; Azuma, M. et al. (1993) *Nature* 366, 76-79; Freeman, G.J. et al. (1993) *J. Exp. Med.* 178, 2185-2192). B7-1 and B7-2 are also ligands for another molecule, CTLA4, present on the surface of activated T cells, although the role of CTLA4 in costimulation is unclear.

Delivery of an antigen-specific signal with a costimulatory signal to a T cell leads to T cell activation, which can include both T cell proliferation and cytokine secretion. In contrast, delivery of an antigen-specific signal to a T cell in the absence of a costimulatory signal is thought to induce a state of unresponsiveness or anergy in the T cell, thereby inducing antigen-specific tolerance in the T cell.

Interactions between T cells and B cells play a central role in immune responses. Induction of humoral immunity to thymus-dependent antigens requires "help" provided by T helper (hereafter Th) cells. While some help provided to B lymphocytes is mediated by soluble molecules released by Th cells (for instance lymphokines such as IL-4 and IL-5), activation of B cells also requires a contact-dependent interaction between B cells and Th cells. Hirohata et al., *J. Immunol.*, 140:3736-3744 (1988); Bartlett et al., *J. Immunol.*, 143:1745-1754 (1989). This indicates that B cell activation involves an obligatory interaction between cell surface molecules on B cells and Th cells. The molecule(s) on the T cell therefore mediates contact-dependent helper effector functions of T cells. A contact-dependent interaction between molecules on B cells and T cells is further supported by the observation that isolated plasma membranes of activated T cells can provide helper functions necessary for B cell activation. Brian, *Proc. Natl. Acad. Sci. USA.*, 85:564-568 (1988); Hodgkin et al., *J. Immunol.*, 145:2025-2034 (1990); Noelle et al., *J. Immunol.*, 146:1118-1124 (1991).

A molecule, CD40, has been identified on the surface of immature and mature B lymphocytes which, when crosslinked by antibodies, induces B cell proliferation. Valle et al., *Eur. J. Immunol.*, 19:1463-1467 (1989); Gordon et al., *J. Immunol.*, 140:1425-1430 (1988); Gruber et al., *J. Immunol.*, 142: 4144-4152 (1989). CD40 has been molecularly cloned and characterized. Stamenkovic et al., *EMBO J.*, 8:1403-1410 (1989). A ligand for CD40, gp39 (also called CD40 ligand or CD40L) has also been molecularly cloned and characterized. Armitage et al., *Nature*, 357:80-82 (1992); Lederman et al., *J. Exp. Med.*, 175:1091-1101 (1992); Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992). The gp39 protein is expressed on activated, but not resting, CD4⁺ Th cells. Spriggs et al., *J. Exp. Med.*, 176:1543-1550 (1992); Lane et al., *Eur. J. Immunol.*, 22:2573-2578 (1992); Roy et al., *J. Immunol.*, 151:1-14 (1993). Cells transfected with the gp39 gene and expressing the gp39 protein on their surface can trigger B cell proliferation and, together with other stimulatory signals, can induce antibody production. Armitage et al., *Nature*, 357:80-82 (1992); Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992).

Summary of the Invention

Cell-surface molecules which mediate contact-dependent helper effector functions of T cells are important for inducing immune responses which require T cell help. For example, the interaction of gp39 on T cells with CD40 on B cells plays a central role in activating B cell responses to antigens. The current invention is based, at least in part, on the discovery that cell-surface molecules which mediate contact-dependent helper effector functions also play a critical role in the response of T cells to antigens. In particular, it has been discovered that, under appropriate conditions, interference of an interaction between gp39 on a T cell and a ligand on a cell which is presenting antigen to the T cell can

induce antigen-specific T cell tolerance. Accordingly, the cell which presents antigen to the T cell requires an interaction between a gp39 ligand (e.g., CD40) on the cell and gp39 on the T cell to be able to provide signals necessary for activation of the T cell. Inhibition of the interaction between the gp39 ligand and gp39 prevents T cell activation and rather induces antigen-specific T cell tolerance.

5 The uses and methods of the invention pertain to induction of antigen-specific T cell tolerance. They involve contacting a T cell with: 1) a cell which presents antigen to the T cell and has a ligand on the cell surface which interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector functions; and 2) an antagonist of the receptor on the surface of a T cell which mediates contact-dependent helper effector functions. The antagonist inhibits the interaction of the receptor with its ligand. A T cell can be contacted with the cell which presents antigen and the antagonist *in vitro*, or alternatively, the cell and the antagonist can be administered to a subject to induce T cell tolerance *in vivo*.

In a preferred embodiment, the receptor on the surface of the T cell which mediates contact-dependent helper effector functions is gp39. In this embodiment, the antagonist is a molecule which inhibits the interaction of gp39 with its ligand on a cell which presents antigen to the T cell. A particularly preferred gp39 antagonist is an anti-gp39 antibody. 15 Alternatively, the gp39 antagonist is a soluble form of a gp39 ligand, for example soluble CD40. The cell which presents antigen to a T cell is preferably a B cell. The B cell can be a small, resting B cell. To induce T cell tolerance to a soluble antigen, the B cell can be contacted with the antigen prior to contact with the T cell (e.g., prior to administration to a subject). In another embodiment, to induce T cell tolerance to alloantigens, the cell which is used to present antigen to the T cell is an allogeneic cell. The allogeneic cell can be, for example, an allogeneic B cell, allogeneic bone marrow, 20 allogeneic spleen cells or allogeneic cells in peripheral blood.

The methods of the current invention can be used, for example, to induce T cell tolerance to a soluble antigen, to induce T cell tolerance a bone marrow transplant or other organ transplant or to inhibit graft-versus-host disease in bone marrow transplantation. In the case of bone marrow transplantation, the transplanted bone marrow cells themselves serve as cells which present antigen to the T cell in the method of the invention. Accordingly, in one embodiment 25 of the invention, acceptance of a bone marrow transplant is promoted by administering to a subject allogeneic bone marrow in conjunction with a gp39 antagonist (e.g., an anti-gp39 antibody).

This invention further pertains to anti-human gp39 monoclonal antibodies capable of inhibiting B cell proliferation, B cell differentiation and T cell responses and to pharmaceutical compositions comprising such antibodies. Anti-human gp39 monoclonal antibodies of the invention are preferred for use in modulating immune responses in general, and particularly for use in inducing antigen-specific T cell tolerance. Preferred antibodies include monoclonal antibodies 3E4, 2H5, 2H8, 4D9-8, 4D9-9, 24-31, 24-43, 89-76 and 89-79, described in Example 6. Particularly preferred antibodies are monoclonal antibodies 89-76 and 24-31. The 89-76 and 24-31 hybridomas, producing the 89-76 and 24-31 antibodies, respectively, were deposited under the provisions of the Budapest Treaty with the American Type Culture Collection, Parklawn Drive, Rockville, Md., on September 2, 1994. The 89-76 hybridoma was assigned ATCC Accession Number 35 HB 11713 and the 24-31 hybridoma was assigned ATCC Accession Number HB 11712. The 24-31 and 89-76 antibodies are of the IgG1 isotype.

Accordingly, in one embodiment, the invention provides the use of an anti-human gp39 used in monoclonal antibody (mAb) of an IgG1 isotype. The anti-human gp39 mAb used in the invention can inhibit B cell proliferation in a standard *in vitro* assay, for example, B cell proliferation induced by treatment of the B cells with interleukin-4 and soluble gp39. Preferably, the anti-human gp39 antibody inhibits B cell proliferation with an IC₅₀ (i.e., concentration necessary to inhibit proliferation by 50%) between about 0.01 and 5.0 µg/ml, more preferably between about 0.1 and 2.5 µg/ml, and even more preferably between about 0.1 and 1.25 µg/ml. The anti-human gp39 mAbs of the invention can also inhibit B cell production of IgG, IgM and/or IgA in a standard *in vitro* assay, for example, Ig production induced by culturing of B cells with activated T cells (e.g., T cells activated by treatment with anti-CD3 antibody). Preferably, the anti-human gp39 antibody inhibits B cell production of IgG, IgM and/or IgA with an IC₅₀ between about 0.01 and 1.0 µg/ml or, more preferably, between about 0.01 and 0.1 µg/ml. 45

In a preferred embodiment, the anti-human gp39 mAb used in the invention binds an epitope recognized by a monoclonal antibody selected from a group consisting of 3E4, 2H5, 2H8, 4D9-8, 4D9-9, 24-31, 24-43, 89-76 and 89-79. More preferably, the anti-human gp39 mAb binds an epitope recognized by monoclonal antibody 24-31 or monoclonal antibody 89-76. The ability of an mAb to bind an epitope recognized by any of the aforementioned antibodies can be determined by standard cross-competition assays. For example, an antibody that binds the same epitope recognized by mAb 24-31 will compete for the binding of labeled 24-31 to activated T cells, whereas an antibody that binds a different epitope than that recognized by mAb 24-31 will not compete for the binding of labeled 24-31 to activated T cells. 50

The invention also provides the preparation of pharmaceutical compositions of the anti-human gp39 antibodies of the invention. These compositions typically comprise an anti-human gp39 mAb (e.g., preferably 24-31 or 89-76) and a pharmaceutically acceptable carrier. 55

Nucleic acid encoding an anti-human gp39 mAb (e.g., DNA encoding an immunoglobulin heavy chain or light chain, or portion thereof, of an anti-human gp39 mAb) can be isolated from a cell (e.g., hybridoma) producing an anti-human

gp39 mAb by standard techniques. For example, nucleic acid encoding the 24-31 or 89-76 mAb can be isolated from the 24-31 or 89-76 hybridoma, respectively, by cDNA library screening, PCR amplification or other standard technique. Nucleic acid encoding an anti-human gp39 mAb chain can be manipulated by standard recombinant DNA techniques to produce recombinant anti-human gp39 mAbs, for example, chimeric or humanized anti-human gp39 mAbs.

Moreover, nucleic acid encoding an anti-human gp39 mAb can be incorporated into an expression vector and introduced into a host cell to facilitate expression and production of recombinant forms of anti-human gp39 antibodies.

Brief Description of the Drawings

Figure 1 is a graphic representation of T cell tolerance to a protein antigen induced by *in vivo* anti-gp39 treatment. T cells responses were measured *in vitro* upon challenge with an antigen which previously was administered *in vivo* on antigen-pulsed B cells either with or without an anti-gp39 antibody.

Figure 2 is a graphic representation of T cell tolerance to allogeneic B cells induced by *in vivo* anti-gp39 treatment. T cells responses were measured *in vitro* upon challenge with allogeneic B cells which previously were administered *in vivo* either with or without an anti-gp39 antibody.

Figure 3A is a graphic representation of the inhibition of primary allogeneic CTL responses induced by allogeneic B cells when recipient animals are treated with anti-gp39 antibody. Groups represented are untreated mice (■), anti-gp39 treated mice (Δ) and spleen cells from unprimed Balb/c mice (●; used as negative control effector cells).

Figures 3B and 3C are graphic representations of the inhibition of primary allogeneic CTL responses induced by LPS-treated B cell blasts when recipient animals are treated with anti-gp39 antibody. Panels B and C represent two independent experiments. Groups represented are LPS blasts *in vivo* without treatment (▶), LPS blasts *in vivo* with anti-gp39 treatment (●), resting B cells *in vivo* without treatment (○) and resting B cells *in vivo* with anti-gp39 treatment (□).

Figure 4A is a graphic representation of the inhibition of secondary allogeneic CTL responses induced by allogeneic B cells when recipient animals are treated with anti-gp39 antibody. Effector groups shown are: Hlg treated recipients (●), naive Balb/c (▶) and anti-gp39 treated recipients (■). Corresponding syngeneic response (Balb/c cells stimulated with Balb/c cells) are indicated by open symbols.

Figure 4B is a graphic representation of the specificity of inhibition of allogeneic CTL responses by anti-gp39 treatment. Shown are CTL responses against H-2^k targets by naive Balb/c cells (○) or by cells tolerized to H-2^b by administration of H-2^b haplotype B cells and anti-gp39 (■).

Figure 5 is a bar graph depicting the number of splenocytes in a host which has received a bone marrow transplant at various times after transfer of the bone marrow to the host either with or without treatment with an anti-gp39 antibody.

Figure 6A is a graphic representation of the concentration of IgA produced by splenic B cells *in vitro* after removal from mice which received a bone marrow transplant either with or without *in vivo* anti-gp39 treatment. Splenic B cells were removed and antibody production measured either 7 or 14 days after bone marrow transplantation.

Figure 6B is a graphic representation of the concentration of IgG1 produced by splenic B cells *in vitro* after removal from mice which received a bone marrow transplant either with or without *in vivo* anti-gp39 treatment. Splenic B cells were removed and antibody production measured either 7 or 14 days after bone marrow transplantation.

Figure 7A is a graphic representation of the serum IgE concentrations in mice which received a bone marrow transplant either with or without *in vivo* anti-gp39 treatment at various times after bone marrow transfer.

Figure 7B is a graphic representation of the serum anti-DNA antibody concentrations in mice which received a bone marrow transplant either with or without *in vivo* anti-gp39 treatment at various times after bone marrow transfer.

Figures 8A and 8B are graphic representations depicting the cytolytic activity *in vitro* of cytotoxic T cells from mice which received a bone marrow transplant either with or without *in vivo* anti-gp39 treatment at different effector to target cell ratios (E:T ratio). Panels A and B represent two independent experiments.

Figures 9A, 9B and 9C are flow cytometric profiles depicting the staining of 6 hour activated human peripheral blood lymphocytes with either CD40lg (panel A), mAb 4D9-8 (panel B) or mAb 4D9-9 (panel C).

Figures 10A, 10B and 10C are flow cytometric profiles depicting the staining of 6 hour activated human peripheral blood lymphocytes cultured in the presence of cyclosporin A stained with either mAb 4D9-8 (panel A), mAb 4D9-9 (panel B) or CD40lg (panel C).

Figures 11A and 11B are flow cytometric profiles depicting the staining of 6 hour activated human peripheral blood lymphocytes with CD40lg in the presence of unlabeled mAb 4D9-8 (panel A) or unlabeled mAb 4D9-9 (panel B).

Figure 12 is a graphic representation of the inhibition of human B cell proliferation induced by soluble gp39 and IL-4 when cells are cultured in the presence of anti-human gp39 mAbs 4D9-8, 4D9-9, 24-31, 24-43, 89-76 or 89-79.

Figure 13 is a graphic representation of the inhibition of an allo-specific mixed lymphocyte response when cells are cultured in the presence of anti-human gp39 mAbs 24-31 or 89-79.

Detailed Description of the Invention

This invention features *in vitro* methods for inducing antigen-specific T cell tolerance. The methods involve contacting a T cell with 1) a cell which presents antigen to the T cell and has a ligand on the cell surface that interacts with a receptor on the surface of the T cell which mediates contact dependent helper effector functions, and 2) an antagonist of the receptor on the T cell which inhibits interaction of the receptor and the ligand. As defined herein, a molecule or receptor which mediates contact dependent helper effector functions is one which is expressed on a Th cell and interacts with a ligand on an effector cell (e.g., a B cell), wherein the interaction of the receptor with its ligand is necessary for generation of an effector cell response (e.g., B cell activation). In addition to being involved in effector cell responses, it has now been found that such a molecule is involved in the response of the T cell to antigen.

A preferred molecule on a T cell which mediates contact-dependent helper effector function is gp39. Accordingly, in preferred embodiments, the methods of the invention involve contacting a T cell with a cell which presents antigen and a gp39 antagonist. Accordingly, the cell used to present antigen is one which interacts with gp39 on the surface of a T cell to activate the T cell (i.e. deliver the necessary signals for T cell activation to the T cell). For example, the cell can be a B cell which expresses CD40 and presents antigen to the T cell. By inhibiting an interaction between a gp39 ligand on the cell presenting antigen with gp39 on the T cell, the T cell is not activated by the presented antigen but rather becomes tolerized to the antigen.

Although not having been claimed, the methods of the invention can be used to induce T cell tolerance to an antigen *in vivo*. For example, a cell which presents antigen to a T cell can be administered to a subject in conjunction with an antagonist of a receptor expressed on the T cell which mediates contact dependent helper effector function (e.g. a gp39 antagonist). The methods of the invention can further be used to tolerize a T cell to an antigen *in vitro* by contacting the T cell *in vitro* with a cell which presents antigen to the T cell together with an antagonist of a receptor expressed on the T cell which mediates contact dependent helper effector function (e.g. a gp39 antagonist). T cells tolerized *in vitro* can then be administered to a subject. The methods of the invention can be used to tolerize T cells in a subject to a specific antigen, or to transplanted cells, such as allogeneic bone marrow (e.g., in bone marrow transplantation). The methods of the invention are also useful for inhibiting graft versus host disease in bone marrow transplantation.

Various aspects of the invention are described in further detail in the following subsections.

I. gp39 Antagonists

According to the methods of the invention, a gp39 antagonist is contacted with a T cell to interfere with the interaction of gp39 on a T cell with a gp39 ligand on an antigen presenting cell, such as a B cell. A gp39 antagonist is defined as a molecule which interferes with this interaction. The gp39 antagonist can be an antibody directed against gp39 (e.g., a monoclonal antibody against gp39), a fragment or derivative of an antibody directed against gp39 (e.g., Fab or F(ab)₂ fragments, chimeric antibodies or humanized antibodies), soluble forms of a gp39 ligand (e.g., soluble CD40), soluble forms of a fusion protein of a gp39 ligand (e.g., soluble CD40lg), or pharmaceutical agents which disrupt or interfere with the gp39-CD40 interaction.

A. Antibodies

A mammal, (e.g., a mouse, hamster, or rabbit) can be immunized with an immunogenic form of gp39 protein or protein fragment (e.g., peptide fragment) which elicits an antibody response in the mammal. A cell which expresses gp39 on its surface can also be used as the immunogen. Alternative immunogens include purified gp39 protein or protein fragments. gp39 can be purified from a gp39-expressing cell by standard purification techniques; gp39 cDNA (Armitage et al., *Nature*, 357:80-82(1992); Lederman et al., *J. Exp. Med.*, 175:1091-1101 (1992); Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992)) can be expressed in a host cell, e.g., bacteria or a mammalian cell line, and gp39 protein purified from the cell culture by standard techniques. gp39 peptides can be synthesized based upon the amino acid sequence of gp39 (disclosed in Armitage et al., *Nature*, 357:80-82 (1992); Lederman et al., *J. Exp. Med.*, 175:1091-1101 (1992); Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992)) using known techniques (e.g. F-moc or T-boc chemical synthesis). Techniques for conferring immunogenicity on a protein include conjugation to carriers or other techniques well known in the art. For example, the protein can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay can be used with the immunogen as antigen to assess the levels of antibodies.

Following immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera. To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells. Such techniques are well known in the art. For example, the hybridoma technique originally developed by Kohler and Milstein (*Nature* (1975) 256:495-497) as well as other techniques such as the human B-cell hybridoma

technique (Kozbar et al., *Immunol. Today* (1983) 4:72), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al. *Monoclonal Antibodies in Cancer Therapy* (1985) (Allen R. Bliss, Inc., pages 77-96), and screening of combinatorial antibody libraries (Huse et al., *Science* (1989) 246:1275). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with the protein or peptide and monoclonal antibodies isolated.

The term antibody as used herein is intended to include fragments thereof which are specifically reactive with a gp39 protein or peptide thereof or gp39 fusion protein. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab')₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab')₂ fragment can be treated to reduce disulfide bridges to produce Fab' fragments. The antibody used in the present invention is further intended to include bispecific and chimeric molecules having an anti-gp39 portion.

When antibodies produced in non-human subjects are used therapeutically in humans, they are recognized to varying degrees as foreign and an immune response may be generated in the patient. One approach for minimizing or eliminating this problem, which is preferable to general immunosuppression, is to produce chimeric antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region. Chimeric antibody molecules can include, for example, the antigen binding domain from an antibody of a mouse, rat, or other species, with human constant regions. A variety of approaches for making chimeric antibodies have been described and can be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes gp39. See, for example, Morrison et al., *Proc. Natl. Acad. Sci. U.S.A.* 81:6851 (1985); Takeda et al., *Nature* 314:452 (1985), Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S. Patent No. 4,816,397; Tanaguchi et al., European Patent Publication EP171496; European Patent Publication 0173494. United Kingdom Patent GB 2177096B. It is expected that such chimeric antibodies would be less immunogenic in a human subject than the corresponding non-chimeric antibody.

For human therapeutic purposes the monoclonal or chimeric antibodies specifically reactive with a gp39 protein or peptide can be further humanized by producing human variable region chimeras, in which parts of the variable regions, especially the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin. Such altered immunoglobulin molecules may be made by any of several techniques known in the art, (e.g., Teng et al., *Proc. Natl. Acad. Sci. U.S.A.*, 80:7308-7312 (1983); Kozbor et al., *Immunology Today*, 4:7279 (1983); Olsson et al., *Meth. Enzymol.*, 92:3-16 (1982)), and are preferably made according to the teachings of PCT Publication WO92/06193 or EP 0239400. Humanized antibodies can be commercially produced by, for example, Scotgen Limited, 2 Holly Road, Twickenham, Middlesex Great Britain.

Another method of generating specific antibodies, or antibody fragments, reactive against a gp39 protein or peptide is to screen expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with a gp39 protein or peptide. For example, complete Fab fragments, VH regions and FV regions can be expressed in bacteria using phage expression libraries. See for example Ward et al., *Nature*, 341: 544-546: (1989); Huse et al., *Science*, 246: 1275-1281(1989); and McCafferty et al., *Nature*, 348: 552-554 (1990). Screening such libraries with, for example, a gp39 peptide can identify immunoglobulin fragments reactive with gp39. Alternatively, the SCID-hu mouse (available from Genpharm) can be used to produce antibodies, or fragments thereof.

Methodologies for producing monoclonal antibodies directed against gp39, including human gp39 and mouse gp39, and suitable monoclonal antibodies for use in the methods of the invention, are described in further detail in Example 6. Particularly preferred anti-human gp39 antibodies of the invention are mAbs 24-31 and 89-76, produced respectively by hybridomas 24-31 and 89-76. The 89-76 and 24-31 hybridomas, producing the 89-76 and 24-31 antibodies, respectively, were deposited under the provisions of the Budapest Treaty with the American Type Culture Collection, Parklawn Drive, Rockville, Md., on September 2, 1994. The 89-76 hybridoma was assigned ATCC Accession Number HB 11713 and the 24-31 hybridoma was assigned ATCC Accession Number HB 11712.

Recombinant anti-gp39 antibodies, such as chimeric and humanized antibodies, can be produced by manipulating nucleic acid (e.g., DNA) encoding an anti-gp39 antibody according to standard recombinant DNA techniques. The immunoglobulin-encoding nucleic acid can encode an immunoglobulin light or heavy chain variable region, with or without a linked heavy or light chain constant region (or portion thereof). Such nucleic acid can be isolated from a cell (e.g., hybridoma) producing an anti-human gp39 mAb by standard techniques. For example: nucleic acid encoding the 24-31 or 89-76 mAb can be isolated from the 24-31 or 89-76 hybridoma, respectively, by cDNA library screening, PCR amplification or other standard technique. Following isolation of, and possible further manipulation of, Moreover, nucleic acid encoding an anti-human gp39 mAb can be incorporated into an expression vector and introduced into a host cell to facilitate expression and production of recombinant forms of anti-human gp39 antibodies.

B. Soluble Ligands for gp39

Other gp39 antagonists which can be used to induce T cell tolerance are soluble forms of a gp39 ligand. A mono-

valent soluble ligand of gp39, such as soluble CD40 can bind gp39, thereby inhibiting the interaction of gp39 with CD40 on B cells. The term "soluble" indicates that the ligand is not permanently associated with a cell membrane. A soluble gp39 ligand can be prepared by chemical synthesis, or, preferably by recombinant DNA techniques, for example by expressing only the extracellular domain (absent the transmembrane and cytoplasmic domains) of the ligand. A preferred soluble gp39 ligand is soluble CD40. Alternatively, a soluble gp39 ligand can be in the form of a fusion protein. Such a fusion protein comprises at least a portion of the gp39 ligand attached to a second molecule. For example, CD40 can be expressed as a fusion protein with immunoglobulin (i.e. a CD40Ig fusion protein). In one embodiment, a fusion protein is produced comprising amino acid residues of an extracellular domain portion of the CD40 molecule joined to amino acid residues of a sequence corresponding to the hinge, CH2 and CH3 regions of an immunoglobulin heavy chain, e.g., $\gamma 1$, to form a CD40Ig fusion protein (see e.g., Linsley et al. (1991) *J. Exp. Med.* 178:721-730; Capon et al. (1989) *Nature* 337, 525-531; and Capon U.S. 5,116,964). The fusion protein can be produced by chemical synthesis, or, preferably by recombinant DNA techniques based on the cDNA of CD40 (Stamenkovic et al., *EMBO J.* 8:1403-1410 (1989)).

II. Cells for Induction of Antigen-Specific Tolerance

The current invention is based, at least in part, on the discovery that presentation of an antigen to a T cell by a cell which both presents antigen and interacts with gp39 results in antigen-specific T cell tolerance when the antigen is presented to the T cell in the presence of a gp39 antagonist. Cells which are capable of inducing T cell tolerance by this mechanism include those which present antigen to a T cell and require an interaction between a gp39 ligand on the cell and gp39 on the T cell to deliver the necessary signals for T cell activation to the T cell. Inhibition of this interaction prevents T cell activation by the presented antigen and, rather, induces antigen-specific tolerance in the T cell. Interference with activation of the T cell via gp39 may prevent the induction of costimulatory molecules on the antigen presenting cell (e.g., B7 family molecules on an antigen presenting cell such as a B cell) so that the antigen presenting cell delivers only an antigenic signal in the absence of a costimulatory signal, thus inducing tolerance.

Accordingly, to carry out the methods and uses of the invention, a cell which presents antigen is administered to a recipient subject. The phrase "cell which presents antigen" and "antigen presenting cell" are used interchangeably herein and are intended to encompass cells which can present antigen to T cells of the recipient and includes B lymphocytes, "professional" antigen presenting cells (e.g., monocytes, dendritic cells, Langerhan cells) and other cells which present antigen to immune cells (e.g., keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes). Furthermore, it is preferable that the antigen presenting cell have a reduced capacity to stimulate a costimulatory signal in recipient T cells. For example, the antigen presenting cell may lack expression of or express only low levels of costimulatory molecules such as the B7 family of proteins (e.g., B7-1 and B7-2). Expression of costimulatory molecules on potential antigen presenting cells to be used in the method of the invention can be assessed by standard techniques, for example by flow cytometry using antibodies directed against costimulatory molecules.

Preferred antigen presenting cells for inducing T cell tolerance are lymphoid cells, for example peripheral blood lymphocytes or splenic cells. Preferred lymphoid cells for inducing T cell tolerance are B cells. B cells can be purified from a mixed population of cells (e.g., other cell types in peripheral blood or spleen) by standard cell separation techniques. For example, adherent cells can be removed by culturing spleen cells on plastic dishes and recovering the non-adherent cell population. T cells can be removed from a mixed population of cells by treatment with an anti-T cell antibody (e.g., anti-Thy1.1 and/or anti-Thy1.2) and complement. In one embodiment, resting lymphoid cells, preferably resting B cells, are used as the antigen presenting cells. Resting lymphoid cells, such as resting B cells, can be isolated by techniques known in the art, for example based upon their small size and density. Resting lymphoid cells can be isolated for example by counterflow centrifugal elutriation as described in Tony, H-P. and Parker, D.C. (1985) *J. Exp. Med.* 161:223-241. Using counterflow centrifugal elutriation, a small, resting lymphoid cell population depleted of cells which can activate T cell responses can be obtained by collecting a fraction(s) at 14-19 ml/min., preferably 19 ml/min. (at 3,200 rpm). Alternatively, small, resting lymphocytes (e.g., B cells) can be isolated by discontinuous density gradient centrifugation, for example using a Ficoll or Percoll gradient, and a layer containing small, resting lymphocytes can be obtained after centrifugation. Small resting B cells can also be distinguished from activated B cells by assaying for expression of costimulatory molecules, such as B7-1 and/or B7-2, on the surface of activated B cells by standard techniques (e.g., immunofluorescence).

The antigen presenting cell, such as a B cell, can be contacted with an antigen (e.g. a soluble protein) prior to contact with the T cell and the cell used to present the antigen to the T cell in the presence of a gp39 antagonist to induce specific T cell tolerance to the antigen (see Example 1). Alternatively, tolerance to alloantigens can be induced by using an allogeneic cell as the antigen presenting cell (see Examples 2 and 3). The allogeneic cell presents antigenic fragments of allogeneic proteins to T cells. In one embodiment, the allogeneic cell is an allogeneic lymphoid cell, such as an allogeneic B cell. Alternatively, a subject can be tolerized with cells in peripheral blood (e.g., peripheral blood lymphocytes), splenic cells or bone marrow cells. In the case of bone marrow transplantation, the donor bone marrow cells

themselves serve as the antigen presenting cells contacted with the T cells (e.g., administered to a subject). Accordingly, allogeneic bone marrow can be administered in conjunction with a gp39 antagonist to induce tolerance to the bone marrow in the recipient and to prevent graft versus host disease (see Examples 4 and 5).

III. Administration of Cells and gp39 Antagonists

Antigen-specific T cell tolerance can be induced by administration of a gp39 antagonist to a subject in conjunction with a cell which presents antigen to a T cell and expresses a ligand which interacts with gp39 on the T cell; the antigen presenting cell and the gp39 antagonist are preferably administered simultaneously or contemporaneously. Alternatively, the gp39 antagonist can be administered prior to administering the cells, for example when the antagonist is an antibody with a long half-life. In a case where the cells to be administered are bone marrow cells, wherein inhibition of graft-versus-host disease is desired, the donor T cells in the bone marrow can be tolerized before transfer to the recipient host by incubating the donor bone marrow with B cells from the host and a gp39 antagonist *in vitro*. gp39 treatment can be continued *in vivo* during and after bone marrow transfer if necessary. In subjects who are to receive a bone marrow or other organ transplant, allogeneic tolerance to the transplant can be induced in the subject by treatment with a regimen which induces allogeneic tolerance prior to transfer of the organ or bone marrow cells. This pre-treatment regimen can involve administering to the subject cells from the donor together with a gp39 antagonist. The cells from the donor can be, for example, B cells, whole peripheral blood or some fraction thereof (e.g., peripheral blood lymphocytes or small resting lymphocytes or B cells).

Administration of a single dose of antigen presenting cells (in combination with the antagonist) has been found to be sufficient for induction of T cell tolerance (see the Examples). The number of antigen presenting cells administered may vary depending upon the type of cell used, the type of tissue or organ graft, the weight of the recipient, the general condition of the recipient and other variables known to the skilled artisan. An appropriate number of cells for use in the method of the invention can be determined by one of ordinary skill in the art by conventional methods (for example using assays described in the Examples). Cells are administered in a form and by a route which is suitable for induction of tolerance in the recipient. Cells can be administered in a physiologically acceptable solution, such as a buffered saline solution or similar vehicle. Cells are preferably administered intravenously.

An antagonist for use in the invention is administered to subjects in a biologically compatible form suitable for pharmaceutical administration *in vivo* to induce T cell tolerance. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the antagonist to be administered in which any toxic effects are outweighed by the therapeutic effects of the protein. The term subject is intended to include living organisms in which an immune response can be elicited, e.g., mammals. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof. A gp39 antagonist can be administered in any pharmacological form, optionally in a pharmaceutically acceptable carrier. Administration of a therapeutically active amount of the antagonist is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of an antagonist of gp39 may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antagonist to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The active compound (e.g., antagonist) may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active compound may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound. A preferred route of administration is by intravenous injection.

To administer an antagonist of gp39 by other than parenteral administration, it may be necessary to coat the antagonist with, or co-administer the antagonist with, a material to prevent its inactivation. For example, an antagonist can be administered to an individual in an appropriate carrier or diluent, co-administered with enzyme inhibitors or in an appropriate carrier such as liposomes. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water emulsions as well as conventional liposomes (Strejan et al., (1984) *J. Neuroimmunol* 7:27).

The active compound may also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water,

ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating active compound (e.g., an antagonist of gp39) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (e.g., antagonist) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

When the active compound is suitably protected, as described above, the protein may be orally administered, for example, with an inert diluent or an assimilable edible carrier. As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

The invention encompasses tolerization of T cells *in vitro*, e.g., by contact with an antigen presenting cell in the presence of a gp39 antagonist. For example, T cells can be obtained from a subject, tolerized *in vitro* by culture with the antigen presenting cells and the antagonist and then readministered to the subject.

IV. Uses of the Method of the Invention

The methods of the invention can be applied to induce T cell tolerance to a variety of antigens. For example, T cell tolerance can be induced to a soluble antigen (e.g., a soluble protein), as described in Example 1. T cells can be tolerized to antigens involved in autoimmune diseases or disorders associated with abnormal immune responses. For example, in one embodiment, the antigen is an autoantigen. In another embodiment, the antigen is an allergen. Alternatively, T cells can be tolerized to antigens expressed on foreign cells (as described in Examples 2 to 5). Accordingly, in yet other embodiments, the antigen is an alloantigen or xenoantigen. Induction of T cell tolerance to alloantigens and xenoantigens is of particular use in transplantation, for example to inhibit rejection by a transplant recipient of a donor graft, e.g. a tissue or organ graft or bone marrow transplant. Additionally, tolerization of donor T cells within a bone marrow graft is useful for inhibiting graft versus host disease (see Example 5).

The invention is further illustrated by the following examples

EXAMPLE 1: Induction of Antigen-Specific Tolerance

Methods

Mice were immunized with KLH-pulsed splenic B lymphocytes for 5 days. During the primary immunization animals were either untreated or treated with an anti-gp39 antibody MR1. Five days after the initial immunization, mice were given a local (food pad) challenge with KLH in complete Freund's adjuvant (CFA). Mice were sacrificed 5 days later, the draining lymph nodes removed and the T cell proliferative response to KLH was subsequently assayed *in vitro*.

Results

Animals immunized with activated B lymphocytes pulsed with antigen and subsequently challenged with the same

antigen mount significant immune responses to the immunizing antigen. The response measured by proliferation of antigen-specific T lymphocytes is shown in Figure 1. Treatment of animals with an anti-gp39 antibody during the primary immunization results in unresponsiveness of antigen-specific T lymphocytes upon *in vitro* antigen challenge. T lymphocytes obtained from lymph nodes from animals treated with an anti-gp39 antibody show decreased proliferative capacity when compared to T lymphocytes obtained from lymph nodes of untreated animals.

EXAMPLE 2: Induction of T Cell Tolerance to Allogeneic Cells

Methods

Balb/c (H-2^d) mice were immunized with allogeneic splenic B cells from DBA/2 (H-2^b) mice. Animals were treated with an anti-gp39 antibody, MR1, or untreated for 5 days after immunization. On day 6, the animals were sacrificed and spleens removed. Spleen cells from anti-gp39 antibody or untreated animals were subsequently cultured *in vitro* with either no stimulus or with irradiated DBA/2 spleen cells. The proliferative response to this secondary allogeneic stimulation was measured on day 3 after initiation of culture.

Results

T lymphocytes from animals immunized with allogeneic splenic B cells mount strong proliferative responses when challenged 5 days later with the same cells *in vitro* (Figure 2). However, T lymphocytes from mice immunized with allogeneic splenic B cells and treated with an anti-gp39 antibody have a decreased proliferative capacity when subsequently challenged *in vitro*. Anti-gp39 antibody treated mice exhibit approximately 50 % decrease in responsiveness to challenge compared to control untreated mice.

EXAMPLE 3: Anti-gp39 Treatment Interferes with the Generation of CTL Responses to Allogeneic B Cells

In this example, the role of gp39 in the generation of cytotoxic T cells (CTL) was investigated. To assess the *in vivo* function of gp39 in the development of CTL, the effects of anti-gp39 treatment on the generation of allospecific CTL by immunization with allogeneic B cells was examined. Effects of anti-gp39 treatment of both primary and secondary CTL responses were determined.

Primary CTL Responses

To test whether anti-gp39 can prevent allogeneic B cells from eliciting allospecific CTL responses *in vivo*, allogeneic B cells (T-depleted spleen cells) were administered to recipient mice with or without anti-gp39. Balb/c mice (female, 6-8 weeks old, Jackson Laboratories, Bar Harbor, ME) were immunized with C57BL/6 (female, 6-8 weeks old, Jackson Laboratories, Bar Harbor, ME) spleen cells (30-50 x 10⁶) depleted of T cells by anti-Thy1.2 (ascites prepared from ATCC clone HO13.4) and rabbit complement treatment. These recipient mice were then untreated or treated with anti-gp39 for 5 days (250 mg/recipient on days 0, 2 and 4). On day five, spleens were removed and CTL responses were measured using a 4 hour chromium release assay. Spleen cells from unprimed Balb/c mice were used as negative control effector cells. Target cells used were E female K1 (H-2^b, T cell lymphoma derived from C57BL/6 strain) and P815 (H-2^d, mastocytoma, derived from DBA/2J strain). ⁵¹Cr-labelled target cells were washed and plated at 1 x 10⁴ cells per well in 96 well plates with effector cells in effector:target (E:T) ratios of 100:1, 20:1 and 4:1. The plates were briefly centrifuged and then incubated at 37 °C in 5 % CO₂ for 4 hours. The plates were once more centrifuged and 100 µl of cell-free supernatant was collected from each well for gamma counting (LKB Clinigamma, Wallace Inc., Gaithersburg, MD). Percent specific lysis is defined as (a-b)/c, where a = cpm released by target cells incubated with effector cells, b = cpm released by target cells incubated with media only (spontaneous release) and c = freeze-thaw releasable cpm from target cells (approximately 80 % of total cpm incorporated). P815 targets were not lysed by any of the cell samples tested. Results for E female K1 targets are illustrated in Figure 3A, wherein the groups shown are untreated mice (■), anti-gp39 treated mice (Δ) and spleen cells from unprimed Balb/c mice (●; used as negative control effector cells). The results demonstrate that mice that received anti-gp39 and allogeneic cells did not generate a primary CTL response *in vivo* in response to allogeneic B cells. In contrast, in the absence of anti-gp39, the allogeneic B cells sensitized the recipient to alloantigen and induced a substantial CTL response.

To determine if anti-gp39 could only amplify the tolerogenic effect of non-activated, splenic B cells, LPS-activated B cells were used to prime CTL in the presence or absence of anti-gp39. B cells from C57BL/6 mice were prepared as described above and cultured for 2 days in the presence or absence of lipopolysaccharide (LPS: 50 mg/ml; Sigma Diagnostics St. Louis, MO). Cells were then harvested and washed thoroughly and injected i.p. (30-50 x 10⁶) into Balb/c recipient mice. Recipient mice were either untreated or treated with anti-gp39 on days 0, 2 and 4 as described above.

On day 5, spleens were removed and CTL responses were determined as described above. The results of two independent experiments are shown in Figure 3B (top and bottom panels). Groups represented are LPS blasts *in vivo* without treatment (>), LPS blasts *in vivo* with anti-gp39 treatment (●), resting B cells *in vivo* without treatment (○) and resting B cells *in vivo* with anti-gp39 treatment (□). The results indicate that, although not complete, anti-gp39 treatment also reduced the primary CTL response to allogeneic LPS blasts.

Secondary CTL Responses

To examine the impact of anti-gp39 and allogeneic B cell administration on CTL formation, spleen cells from treated and untreated mice were stimulated *in vitro* and the scope of CTL responses investigated. Balb/c mice were primed *in vivo* with C57BL/6-derived B cells as described above. Spleen cells from the anti-gp39 and control hamster Ig (Hlg) treated animals were removed and 5×10^6 cells/ml were cultured for 5 days ("responders") with various mitomycin C treated (2.5 mg/ml at 37°C , Sigma Diagnostics, St. Louis, MO) strains of splenic B cells (prepared by anti-Thy1.2 + complement treatment) at 5×10^6 stimulators/ml. Stimulator groups were C57BL/6 (H-2^b) and Balb/c (H-2^d) which indicate the secondary allogeneic response and the primary syngeneic response, respectively. Stimulator and responder cells were cultured in freshly prepared sensitization RPMI-1640 medium (Bio Whittaker, Walkersville, MD), $1 \times 10^5 \text{ M}$ 2-mercaptoethanol (Bio-Rad Laboratories, Hercules, CA), 2 mM L-glutamine (Sigma Diagnostics, St. Louis, MO), 500 U/ml penicillin and 5000 U/ml streptomycin (Sigma Diagnostics, St. Louis, MO). After 5 days, the responder cells were harvested and dead cells were removed by centrifugation on a density gradient. The resulting live cells were used as effectors in a CTL assay as described above. Targets included E female K1 (H-2^b, T cell lymphoma derived from C57BL/6 strain) and P815 (H-2^d, mastocytoma, derived from DBA/2J strain). The results are illustrated in Figure 4A. Allogeneic stimulated effector groups shown are: Hlg treated recipients (●), naive Balb/c (>) and anti-gp39 treated recipients (■). Corresponding syngeneic response (Balb/c cells stimulated with Balb/c cells) are indicated by open symbols. As anticipated, *in vivo* immunization of mice with allogeneic T-depleted spleen cells (H-2^b) in the absence of anti-gp39 treatment resulted in a robust secondary CTL response *in vitro*. The heightened secondary anti-H-2^b CTL response was not observed if mice were given anti-gp39 *in vivo*.

To determine the specificity of the inhibition of CTL responses by anti-gp39 treatment, spleen cell cultures as described above were analyzed for anti-H-2^k allogeneic responses (third party allogeneic responses) using B10BR (H-2^k) splenic B cells as the stimulators and SL8 (H-2^k, spontaneous T cell lymphoma derived from AKR strain) as the targets in the CTL assay. The results are shown in Figure 4B. Groups shown are naive Balb/c (○) and anti-gp39 treated recipients (■). The results demonstrate that the inhibition of anti-H-2^b-specific CTL responses by anti-gp39 treatment was allospecific since administration of H-2^b spleen cells and anti-gp39 did not alter the *in vitro* CTL response to a bystander alloantigen (H-2^k).

Taken together, these data show that anti-gp39 interferes with the generation of allospecific CTL responses (both primary and secondary). In the presence of anti-gp39, CTL precursors specific to the relevant alloantigen are still present since in the *in vitro* secondary culture one can demonstrate some anti-H-2^b CTL activity. It can be concluded that anti-gp39 treatment reduced the secondary *in vitro* response by blocking CTL priming or reducing the frequency of primed allospecific CTL. The use of resting B cells is not imperative to demonstrate this unresponsiveness since the allogeneic CTL response induced by LPS blasts was also impaired by anti-gp39.

EXAMPLE 4: Transfer of Allogeneic Murine Bone Marrow Induces Stable Chimeras when Recipients are Treated with an Antibody to gp39

The treatment for many hematological disorders, that cannot be cured with conventional chemotherapeutic methods, involves the transfer of allogeneic bone marrow. This aggressive therapy involves administration of high, myeloablative doses of chemotherapy coupled with the perfusion of allogeneic bone marrow allowing the eradication of clonogenic tumor cells.

It has already been shown that thymic irradiation, deleting thymic T cells, increases the incidence of stable chimeras when monoclonal antibodies (mAbs) to T cell, including anti-CD4 mAbs were used. This antibody regime led to T cell deletion and thus donor specific tolerance, which could be indicated by tolerance to donor skin grafts. Failure to achieve permanent allogeneic engraftment after 300 rad WBI, *in vivo* anti-T cell mAb treatment, and administration of allogeneic bone marrow may have resulted from the unaffected T cells within the thymus. Use of anti-CD4 and anti-CD8 mAbs can lead to effective depletion of peripheral blood and splenic T cells, but the thymic T cells are simply coated with mAbs but not deleted. Thus thymic irradiation is performed on the mice.

Methods

A murine model for allogeneic bone marrow transfer (BMT) of F1 into parent was used so as to avoid graft-versus-

host disease from being induced. We used the F1 strain CB6 which are (C57BL/6 x Balb/c)F1 resulting the overall MHC haplotype of H-2^{d/b}. Bone marrow was removed and i.v. injected into the irradiated BALB/c parent with or without an anti-gp39 antibody, MR1. Whole body irradiation (WBI) levels were varied so as to determine the best level of chimerism and to compare anti-gp39 antibody treated and untreated animals with each irradiation level. Chimerism was determined by flow cytometric analysis of peripheral blood lymphocytes of the H-2^b MHC haplotype present within the H-2^d (BALB/c) mouse. It has previously been shown that this combination of mice is suitable and chimeras can be obtained at levels of 500 and 600 rads WBI.

Results

Chimerism was detected by identification of C57BL/6 derived cells (H-2^b) by flow cytometry. Chimerism was found to develop in mice irradiated with 400, 500 and 600 whole body irradiation within 14 days only if treated with anti-gp39 antibody from the start of the study. Mice that received no antibody treatment rejected the cells at all levels of irradiation except when given 600 whole body irradiation, whereby they accepted the bone marrow to the same extent as the antibody treated group at 400 rads (Table 1). It was found that the level of chimerism after 6 weeks of therapy at 400, 500 and 600 rads with anti-gp39 antibody therapy to be 70.7 ± 5.74, 94.1 and 84.4 ± 8.56 respectively, while at 600 rads with no treatment they it was found to be 85.7 ± 5.9 chimeric (Table 2). Phenotyping the cells at this point indicated that T cells, B cells and macrophages were all chimerised and the same extent for 400 rads when treated compared to the 600 rads untreated group (Table 2). It also appeared that anti-gp39 antibody treatment did not significantly change the total percent population of any of the lymphoid cells within the periphery. When treatment of the animals with anti-gp39 antibody was terminated the animals were found to be stably chimeric for up to 8 weeks post transplant.

TABLE I

Whole body radiation level (rads)	No. of chimeric animals treated with anti-gp39 treatment	No. of chimeric animals with no anti-gp39 treatment
0	0(5)	0(5)
200	0(5)	0(5)
400	9(9)	0(9)
450	3(5)	0(5)
500	4(5)	2(5)
600	7(9)	7(9)

Levels of whole body irradiation resulting in chimerism. Numbers in parenthesis indicate the total number of animal tested at each level.

TABLE 2

Rads.	Treatment	II-2K ^{b+}	B cells II-2K ^{b+}	T cells II-2K ^{b+}	Mac. II-2K ^{b+}
400	+	70.7 ± 5.74	89 ± 2.6	45.9 ± 13.3	82.3 ± 3.3
500	+	94.1	100	89	100
600	+	84.4 ± 8.56	99.3 ± 0.94	72.3 ± 15.9	91.1 ± 8.3
600	-	85.7 ± 5.9	97.3 ± 1.77	67.1 ± 10.3	91 ± 9

Percent of B cell, T cell and macrophages (Mac.) positive for H-2K^b± standard error.

EXAMPLE 5: Allogeneic Bone Marrow Transplantation Combined with Treatment of the Recipient with Anti-gp39 Inhibits Acute and Chronic Graft Versus Host Disease

The following methodology was used in this example:

Mice: DBA/2 (H-2^d), C57BL/6 (H-2^b) and B6D2F₁ ((C57BL/6 (H-2^d) x DBA/2) F₁ hybrid) mice were obtained from the NCI laboratories (Bethesda, Maryland) and maintained in a viral free environment in the Animal facility at Dartmouth Medical School. All the mice used in this study were female, and aged 6 to 8 weeks old.

Induction of chronic GVHD: Chronic GVHD was induced by the i.v. injection of parental (DBA/2) spleen cells into non-irradiated (C57BL/6 x DBA/2) F₁ hybrid recipients (Fast, L.D. (1990) *J. Immunol.* 144:4177). Parental mice were anesthetized and killed by cervical dislocation in preparation for removal of the spleen. Dissociated spleen cells were washed and resuspended in RPMI 1640 medium (Whittaker, Walkersville, Maryland) for i.v. injection into the F₁ recipients.

Induction of acute GVHD: Acute GVHD was induced by the i.v. injection of parental C57BL/6 spleen cells into non-irradiated (C57BL/6 x DBA/2) F₁ hybrid recipients. Cells were prepared for transfer as for the induction of chronic GVHD.

Antibodies: Anti-gp39:MR1 was produced in ascites and purified by ion exchange HPLC, as previously described (Foy, T.M. et al. (1993) *J. Exp. Med.* 178:1567-1575; Noelle, R.J. et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6550). Polyclonal anti-isotype antibodies: All anti-IgG₁ and IgA antibodies and standard controls were obtained from Southern Biotechnology Associates, Inc., (Birmingham AL). Anti-IgE antibodies: All anti-IgE antibodies (BIE3 and Biotin AM95) and standards (A3B1) used in the IgE specific ELISA were a kind gift from Dr. T. Waldschmidt, IA. Anti-MHC haplotype antibodies: H-2K^b FITC conjugated antibody and H-2D^d Biotin conjugated antibody were obtained from Pharmingen (San Diego, CA).

Cell lines: Cell lines used included P815 (H-2^d) and LB27.4 (H-2^{bmd}), which were obtained from the American Type Culture Collection. The cell line c1.18.5 (H-2^b) was obtained as a kind gift from Dr. William R. Green.

Polyclonal Ig production in vitro: Spleens from control and cGVHD mice were removed and single cell suspensions prepared. Cells were treated with Tris-buffered ammonium chloride to remove erythrocytes and total white blood cell counts determined by visual hemocytometer counting. Cells were incubated (5x10⁶) in 1 ml of complete (c)RPMI-1640 medium (supplemented with 10% fetal serum (Hyclone, Logan UT, 25 mM HEPES, 2 mM L-glutamine, 5000 U/ml penicillin and 5000 mg/ml streptomycin) for 3 days at 37 °C, 5 % CO₂. Culture supernatants were collected by pelleting the cells and Ig was quantified by an isotype-specific ELISA assay.

Isotype-specific and antigen-specific ELISAs: ELISA for the detection of IgG₁ and IgA: Goat anti-mouse IgG₁ or IgA (10µg/ml; Southern Biotechnology Associates, Inc., Birmingham AL) in PBS was absorbed onto wells of a 96-well polyvinyl microtitre plate for 1 hour at 37 °C then overnight at 4 °C. Plates were washed and blocked with PBS containing 1 % FCS for 1 hour at 37 °C. Plates were washed again and the appropriate dilutions of supernatants and standard controls (IgG₁ and IgA, Southern Biotechnology Associates, Inc., Birmingham AL) were added for 2 hours at 37 °C. After this time, the plates were washed 3 times and alkaline-phosphatase conjugated goat anti-mouse IgG₁ or IgA, (1/500 dilutions) (Southern Biotechnology Associates, Inc., Birmingham Alabama) were added for 2 hours at 37 °C. Plates were thoroughly washed and phosphatase substrate (1mg/ml; Sigma Diagnostics, St. Louis, MO) added resulting in the appropriate colour change. Readings were determined by an ELISA reader (Dynatech Laboratories, Inc.) at an absorbance of 410 nm. Concentrations of Ig were determined by comparison to the appropriate isotype standard curve and expressed as the mean + standard error (n=3).

ELISA for the detection of IgE: Wells of 96-well polyvinyl microtitre plate were coated with an anti-mouse IgE capture antibody (BIE3 (2mg/ml)) overnight at 4 °C and then blocked with PBS containing 1 % FCS for 1 hour at 37 °C. Plates were washed again and the appropriate dilutions of supernatants and standard controls (A3B1 (IgE)) were added for 2 hours at 37 °C. Plates were thoroughly washed and the EM95-Biotin (5mg/ml) was added to each well and incubated for 2 hours at 37 °C. After this time, alkaline-phosphatase conjugated to streptavidin was added (1/500 dilution) for a further 2 hours and then washed thoroughly before the addition of phosphatase substrate (1 mg/ml; Sigma Diagnostics, St. Louis, MO) resulting in the appropriate colour change. Readings were determined by an ELISA reader (Dynatech Laboratories, Inc.) at an absorbance of 410 nm. Concentrations of Ig were determined by comparison to standard curve and expressed as the mean + standard error (n=3).

ELISA for the detection of anti-DNA Ab: Calf thymus DNA (Sigma, St. Louis, MO.) (5µg/ml) was dissolved in coupling buffer containing 0.1 M sodium carbonate/sodium bicarbonate (pH 9.8). This was boiled for 10 minutes and then incubated on ice for 3 minutes. The OD 260 of the DNA was then determined and the concentration adjusted to obtain the required 5µg/ml DNA. 100µl was then added to the wells of a 96 well polyvinyl microtitre plate and incubated overnight at 4 °C. The plate was then washed 3 times and blocked for 1 hour at 37°C with PBS containing 1 % FCS and 0.02 % sodium azide. The plate was again washed and serial dilutions of serum samples was then added (100 ml) and incubated for 2 hours at 37 °C. The detection antibody, goat anti mouse IgG₁ alkaline phosphatase was then added each well and incubated once again for 2 hours at 37 °C. Plates were thoroughly washed and phosphatase substrate (1mg/ml; Sigma Diagnostics, St. Louis, MO) added resulting in the appropriate colour change. Readings were determined by an ELISA reader (Dynatech Laboratories, Inc.) at an absorbance of 410 nm. Antibody titres were compared to a positive sera samples and results expressed in arbitrary units.

Flow Cytometric Analysis for the detection of donor derived cells. Spleens were removed from normal BDF₁,

cGVHD mice treated with and without anti-gp39 and a single cell suspension was prepared. The cells were layered onto Ficoll-Hypaque (4:1) and then centrifuged at 2000 rpm for 20 minutes at room temperature. The resulting lymphocyte layer was removed and washed once with BSS containing 5 % FCS. 1×10^6 cells, per tube, were used for staining in a 50 μ l final volume. 50 μ l of rat serum was added to each tube to prevent non specific binding of antibodies. Cells were stained with the (a) control antibodies: Rat Ig FITC (1:100 final dilution) and PE-Streptavidin (1:500 final dilution) and (b) FITC H-2K^b and Biotin H-2D^d (both 1:100 final dilution). Cells were incubated for 20 minutes on ice and then washed twice to remove any unbound antibodies. Finally PE-Streptavidin (1:500 final dilution) was added to the appropriate tube to detect the biotin conjugated antibody for another 20 minutes on ice. Cells were again washed twice ready for analysis on a Becton Dickinson FACScan. After positive gating via forward and side scatter, 10,000 events were collected per sample for determination of percent cells positive for the relevant MHC haplotype.

Chromium release assay for assessment of CTL assay. ⁵¹Cr-labelled target cells are washed and plated at 1×10^4 per well in 96 well plates with effector cells in E:T ratios of 100:1, 20:1, and 4:1. Target cells used included P815 (H-2^d), LB27.4 (H-2^{bxd}) and c118.5 (H-2^b). The plates are briefly centrifuged and then incubated at 37 °C in 5 % CO₂ for 4 hours. The plates were once more centrifuged and an aliquot of cell-free supernatant was collected from each well for counting by a gamma counter. Percent specific lysis is defined as (a-b)/c where a = cpm released by target cells incubated with effector cells, b = cpm released by target cells incubated with media only (spontaneous release), and c = freeze-thaw releasable cpm for target cells (approximately 80% of total cpm incorporated).

Secondary stimulation of acute GVHD spleen cells in vitro. Acute GVHD spleens were removed from anti-gp39 treated, Hlg treated or untreated animals. Spleens were red cell depleted and then aliquoted at 1×10^4 per cell well. Irradiated stimulator cells (P815) were added to the appropriate wells. After 7 days CTL assays were performed against the appropriate targets as previously mentioned.

Results

GVHD in mice results in splenomegaly. In the mouse, one of the consequences of cGVHD is the enlargement of the spleen. It is primarily the host's own cells that infiltrate and enlarge the spleen, although this is in response to the presence of donor cells (Rolink, A.G. et al. (1983) *J. Exp. Med.* 158:546). Figure 5 indicates that at 7-14 days after the initiation of cGVHD, spleens contains almost twice the number of leukocytes compared to mice without cGVHD. Treatment of mice at the onset of cGVHD with anti-gp39 (250 μ g/mouse, days 0,2,4, and 6), reduce the number of leukocytes/spleen in cGVHD mice to values that were identical to mice without disease.

GVHD-induced hyperproduction of polyclonal Immunoglobulin. It has been reported that hyper production of Ig occurs in mice with cGVHD due to cognate interactions between donor T cells and B cells (Morris, S.E. et al. (1990) *J. Exp. Med.* 171:503). To determine whether anti-gp39 inhibits hyper Ig production, mice with cGVHD were administered anti-gp39. On day 7 or 14, spleens were removed from control and cGVHD mice and the B cells assayed for the spontaneous production of IgG₁ and IgA *in vitro*. Splenocytes from mice with cGVHD produced high levels of IgA and IgG₁ (Figures 6A and 6B) *in vitro*. However, splenocytes from mice with cGVHD and treated with anti-gp39 (days 0, 2, 4 and 6) produced levels of IgG₁ and IgA identical to mice without disease. The addition of anti-gp39 to cultures of spleen cells from mice with cGVHD did not reduce the levels of *in vitro* Ig production, suggesting that anti-gp39 was exerting its effects *in vivo*.

When Hamster Ig (Hlg) was used as a control for these experiments it was found that it showed no inhibitory role in the induction of GVHD but actually accentuated the disease not only in terms of polyclonal Ig production but also in the resultant splenomegaly. An 8-fold increase was detected in the level of Ig produced by 1 week Hlg treated GVHD-induced mice compared to untreated 1 week GVHD-induced mice. It was apparent that the Hlg was in itself an immunogen. Consequently it was decided to designate the untreated F₁ recipient mice as the relevant control group.

Effect of anti-gp39 on GVHD-induced serum Hyper-IgE and anti-DNA autoantibodies. The course of cGVHD can be monitored by the elevation in serum IgE and antibodies to double stranded DNA (Morris, S.E. et al. (1990) *J. Exp. Med.* 171:503). Levels of serum IgE were measured using an IgE specific ELISA. Chronic GVHD induced mice were treated with anti-gp39 on days 0, 2, 4 and 6 and then no further antibody was administered. Mice were bled at weekly intervals and the levels of serum IgE ascertained (Figure 7A). cGVHD induces a 10-15 fold increase in serum IgE levels. Administration of anti-gp39 inhibited cGVHD-induced increases in serum IgE for up to eight weeks after the initiation of disease. In addition to the inhibition of elevated serum IgE, administration of anti-gp39 also blocked the generation of serum anti-DNA autoantibodies. Chronic GVHD induces a 5-10 fold increase in the levels of anti-DNA antibodies found, which was reduced by anti-gp39 treatment (Figure 7B).

Previous studies have shown that the half-life of anti-gp39 (MR1 clone) is 12 days (Foy, T.M. et al. (1993) *J. Exp. Med.* 178:1567-1575). ELISA assays specific for the detection of anti-gp39 indicate that the anti-gp39 was undetectable in the serum of treated mice eight weeks following therapy. Therefore, persistent anti-gp39 cannot account for the protracted suppression of cGVHD. Transfer studies were performed to investigate if splenocytes from mice with cGVHD and those that have been administered anti-gp39 could transfer cGVHD. Splenocytes from mice given cGVHD and anti-

gp39 were incapable of inducing heightened serum levels of IgE and anti-DNA autoantibodies upon adoptive transfer; whereas splenocytes from mice with cGVHD induced enhanced IgE and anti-DNA antibodies. These data suggest that the alloreactive T cells have been induced to become unresponsive as a result of anti-gp39 treatment.

Detection of alloreactive donor cells. When cGVHD induced mice were analysed for the presence of donor derived cells within their spleens, it was found that compared to normal BDF₁, which stain double positive for H-2K^b and H-2D^d, cGVHD possessed approximately 5-7 % donor cells. These cells are DBA/2 derived and therefore stain single positive for H-2D^d. These cells were detected irrespective of anti-gp39 treatment. This illustrates the point that anti-gp39 treatment allows engraftment of the donor cells without eliciting any of the helper function for the recipient B cells that results in polyclonal Ig production in the untreated cGVHD group.

Effect of anti-gp39 treatment on the induction of acute GVHD. Acute GVHD is associated with the induction of increased anti-allogeneic CTL response. While it is clear that gp39-CD40 interactions are critical for T_H-B cell interactions, it is not clear if the induction of other immune effector mechanisms may also be altered by anti-gp39 therapy. AGVHD was induced by the administration of C57BL/6 spleens to the F₁ recipients. As shown in Figure 8, 12 days following the transfer of allogeneic cells, a robust H-2^b anti H-2^d CTL response is measured. Treatment of mice with anti-gp39, but not Hlg, prevented the generation of H-2^b anti-H-2^d CTL (Figure 8). In 1 of 2 experiments, treatment with anti-gp39 reduced the CTL responses below that which was observed with naive spleen cells. This suggested that spleen cells from a GVHD mice when challenged with. If these spleen cells are then cultured for 7 days in the presence of irradiated P815 cells and then a CTL assay performed these cells fail to mount a secondary stimulation to the P815 cells, however the normal BDF₁ spleen mount a primary response. The untreated aGVHD induced mice mount a secondary immune response as expected. These results indicate that the treatment of acute GVHD mice with anti-gp39 makes the CD8⁺ population unresponsive to a secondary challenge.

Discussion

Reversal of splenomegaly (Figure 5), inhibition of hyper Ig production (Figures 6A and 6B), inhibition of serum levels of IgE and anti-DNA autoantibody production (Figures 7A and 7B) in GVH-induced mice by anti-gp39 administration, suggests that anti-gp39 blocked the ability of the grafted T cells to induce host B cell activation. This inhibition of splenomegaly and polyclonal IgG₁ and IgA production remains low 7 days after termination of antibody administration. Reduction in IgE and anti-DNA antibodies persists for 8 weeks even when the treatment is terminated. These results indicate that T cell function has been affected either by clonal deletion of the reactive T cells or that T cell anergy has occurred. It has previously been shown (Van den Eertwegh et al. (1993) *J. Exp. Med.* 178:1555-1565) that levels of cytokine producing cells remain normal in antibody treated mice in *in situ* studies of immunized mice. This indicates that T cells are not deleted as a consequence of the treatment. When cGVHD mice were analysed for the presence of donor derived cells they are found to be present whether the animal is untreated or treated with anti-gp39. Anti-gp39 thus has the ability to induce an unresponsive state upon these donor T cells. Eliciting inhibition of antibody responses. Indeed, if spleens from these animals are transferred into naive recipients levels of antibody are elevated when the donor spleens are untreated cGVHD but anti-gp39 treated cGVHD mice are unable to mount a secondary cGVHD state upon transfer. This data suggests that anti-gp39 interferes with the ability of T cells to elicit a strong GVHD clinical immunopathology and splenomegaly that the antibody administration elicits unresponsiveness on the CD4⁺ subpopulation.

It has been reported that B cells are required to provide help for the induction of CTLs as seen by studying B cell deficient mice for the induction of protective T cell immunity to a Friend murine leukemia virus-induced leukemia (Schultz, K.R. et al. (1990) *Science* 249). It thus seems conceivable that in a aGVHD induced mice, anti-gp39 inhibits the activation of B cells and thus prevents antigen presentation and thus prime the CD8⁺ T cells. It has also been suggested that generation of CD8⁺ CTL required interaction with class II-restricted Th cells (von Boehmer, H. et al. (1979) *J. Exp. Med.* 150:1134; Keene, J. et al. (1982) *J. Exp. Med.* 155:768) and that when TCR affinity is low, CD4⁺ mediated T cell help is required *in vivo* (Gao, X. et al. (1991) *J. Immunol.* 147:3268).

Studies have been performed looking at the role of CD28-B7/BB1 interactions in the induction of CD8⁺CTL responses. It was found that CD28-B7/BB1 interactions were necessary and sufficient for the generation of class I MHC-specific CTL (Harding, F.A. and Allison, J.P. (1993) *J. Exp. Med.* 177:1791). It has been suggested that the ligand for CD40 may be an important inducer for B7 (Ranheim, E.A. and Kipps, T.J. (1993) *J. Exp. Med.* 177:925) as shown by studies involving the inhibition of B7 expression on normal and leukemic B cells by antibodies to CD40. Together, these studies indicate that anti-gp39 may block interaction of CD4⁺ T cells with B cells thus failing to induce the expression of B7 that allows a B cell to efficiently activate a T cell to proliferate and produce cytokines. Taken together, this data suggests that CD4⁺ T cells are required for the induction of CTL formation first by T- B cells cognate interaction between gp39 and its ligand CD40. Signaling of CD40 on the B cells then allows upregulation of B7/BB1. Reciprocal interaction of B7/BB1 with its ligand CD28 on the T cells then allows enhanced T cell proliferation and cytokine production. If, however, only one signal is provided to the T cells, i.e., gp39 interaction with CD40, and the second signal is not obtained, then an unresponsiveness is induced in the T cells and it becomes tolerated or anergised.

These studies indicate that when aGVHD is induced in mice, an anti-H-2^d response is obtained. However, if the animals are treated with anti-gp39, then no CTL response is observed. It may be apparent that anti-gp39 is inhibiting the CTL formation by a method previously described (Schultz, K.R. et al. (1990) *Science* 249). The B cells fail to be activated via CD40 ligation and are thus unable to promote the induction of CTLs. Furthermore, our studies show that when spleen cells are challenged *in vitro* with P815 cells, the cells that were exposed to anti-gp39 *in vivo* were found unable to mount a secondary anti-H-2^d CTL. Thus, this may indicate that anti-gp39 has induced a state of tolerance on the T cell compartment since gp39 is unable to engage CD40, there thus is no B7/BB1 upregulation and so the T cells do not get farther activated and remain unresponsive. It is also known that resting B cells generally are ineffective stimulators of allogeneic T cells in the mixed lymphocyte reaction unless preactivated by anti-IgM antibodies, PMA or LPS (Inaba, K. and Steinman, R.M. (1989) *J. Exp. Med.* 160:1717; Metley, J. P. et al. (1989) *J. Exp. Med.* 169:239; Frohman, M. and Cowing, C. (1985) *J. Immunol.* 134:2269). In addition, soluble monomeric antigen directed to B cells for presentation *in vivo* may result in specific T cell anergy (Eynon, E.E. and Parker, D. (1992) *J. Exp. Med.* 175:131). Thus, it seems evident, depending on the method of administration of antigen and APCs involved, that anergy or tolerance may be induced. Upon challenge of P815 cells to the CD8+ T cells compartment of the spleen, B cells are not required for antigen presentation, thus alloantigen can be presented directly and CTL induced. The unresponsiveness of the spleens to secondary stimulation indicates that allospecific tolerance has been induced in this system.

This in opposition to previous results (Foy, T.M. et al. (1993) *J. Exp. Med.* 178:1567-1575) which indicate that tolerance is not induced by the antibody in an antigen specific system. The two systems differ since the aGVHD model presents alloantigen already bound to antigen presenting cells, whereas with antigen specific systems the antigen is administered and *in vivo* is taken up, processed and presented by professional APC. It thus seems that anti-gp39 may have different effects depending on the antigen being used and the method of presentation.

It can be concluded that anti-gp39 may induce allospecific tolerance in both the CD4+ and CD8+ compartments of the immune system and this may be obvious beneficial therapeutic intervention when considering transplant immunology and immunotherapy. It is conceivable that for treatment of patients undergoing bone marrow transplants that anti-gp39 therapy will be sufficient for induction of tolerance to the graft and prevent the induction of such consequences of transplant treatments as GVHD.

EXAMPLE 6: Production and Characterization of Anti-gp39 Antibodies

Experiment 1 - Antibodies directed against human gp39

For induction of antigen-specific T cell tolerance in a human subject, it is preferable to administer an antibody directed against human gp39. The following methodology was used to produce mouse anti-human gp39 monoclonal antibodies. Balb/c mice were immunized with a soluble gp39 fusion protein, gp39-CD8, in Complete Freund's Adjuvant (CFA). Mice were subsequently challenged 6 weeks later with soluble gp39-CD8 in Incomplete Freund's Adjuvant (IFA). Soluble gp39-CD8 was given in soluble form 4 weeks after secondary immunization. Mice were then boosted with activated human peripheral blood lymphocytes 2 weeks later, followed by a final boost with soluble gp39-CD8 after an additional 2 weeks. Splenocytes were fused with the NS-1 fusion partner on day 4 after final immunization as per standard protocols.

Clones producing anti-human gp39 antibodies were selected based on a multiple screening process. Clones were initially screened by a plate binding assay using gp39-CD8. Positive clones were then screened against a control CD8 fusion protein, CD72-CD8. Clones which scored positive on the CD8-CD72 plate binding assay were eliminated. The remaining clones were subsequently screened on resting and 6 hour activated human peripheral blood lymphocytes (PBL) by flow cytometric analysis. Hybridomas staining activated, but not resting, PBL were considered positive. Finally, the remaining clones were tested for their ability to block the binding of CD40Ig to plate bound gp39.

Approximately 300 clones were initially screened against gp39-CD8 and CD72-CD8 in the plate binding assays. Of those clones, 30 were found to detect plate-bound gp39 and not CD8. These clones were subsequently screened for detection of gp39 on activated human PBL. Approximately 15 clones detected a molecule on activated PBL, but not resting cells. Specificity was further confirmed by determining the capacity of the clones to block CD40Ig detection of plate-bound gp39. 3 of 10 clones tested block CD40Ig binding in this assay. These clones were 3E4, 2H5 and 2H8. Such clones are preferred for use in the methods described herein. Clones which tested positive on activated, but not resting PBL, were also screened for reactivity with an activated rat T cell clone, POMC8. The clone 2H8 expressed crossreactivity with this rat T cell line.

Experiment 2 - Antibodies directed against human gp39

A similar immunization procedure to that described in Experiment 1 was used to produce additional antibodies directed against human gp39. One Balb/c mouse was immunized with soluble gp39-CD8 in CFA, followed by challenge

with 6 hour activated human peripheral blood lymphocytes 4 weeks later. The mouse was subsequently boosted with soluble gp39-CD8 4 days prior to fusion of splenocytes with the NS-1 fusion partner per standard protocols. Screening of hybridoma clones was performed by flow cytometric staining of 6 hour activated human PBLs. Clones staining activated but not resting human PBLs were selected. Six clones, 4D9-8, 4D9-9, 24-31, 24-43, 89-76 and 89-79, were selected for further analysis.

The specificity of the selected antibodies was confirmed by several assays. First, flow cytometric analysis demonstrated that all six mAbs stain activated, but not resting peripheral blood T cells (see Figure 9B and 9C for a representative example, depicting staining of activated T cells with 4D9-8 and 4D9-9, respectively). Expression of the molecule recognized by each of the six antibodies is detectable within 4 hours of activation, is maximal between 6-8 hours after activation, and is undetectable by 24 hours after activation. All six mAbs recognize a molecule expressed on activated CD3⁺ PBLs, predominantly of the CD4⁺ phenotype, but a portion of CD8⁺ T cells also express the molecule. Expression of the molecule recognized by the six mAbs is inhibited by the presence of cyclosporin A in the culture medium, as is the expression of gp39 (see Figure 10A and 10B for a representative example, depicting staining of cyclosporin treated T cells with 4D9-8 and 4D9-9, respectively). The kinetics and distribution of expression of the molecule recognized by these mAbs are identical to that of gp39, as detected by the fusion protein of human CD40lg. In addition, all six mAbs block the staining of gp39 by CD40lg (see Figure 11A and 11B for a representative example, depicting inhibition of gp39 staining by CD40lg in the presence of 4D9-8 and 4D9-9, respectively). In an ELISA assay, all six mAbs recognize gp39-CD8, a soluble fusion form of the gp39 molecule. Moreover, all six mAbs immunoprecipitate a molecule of approximately 36 kd from ³⁵S-methionine labeled activated human PBLs. The immunoprecipitated molecule is identical to that precipitated by the human CD40lg fusion protein.

The functional activity of the six selected mAbs (4D9-8, 4D9-9, 24-32, 24-43, 89-76 and 89-79) was assayed as follows. First, the ability of the mAbs to inhibit the proliferation of purified human B cells cultured with IL-4 and soluble gp39 was measured. Purified human B cells were cultured with gp39 and IL-4 in the presence or absence of purified monoclonal antibodies or CD40lg at dosages between 0 and 12.5 µg/ml. B cell proliferation was determined after 3 days in culture by thymidine incorporation. The results (shown in Figure 12) demonstrate that all six mAbs can inhibit B cell proliferation induced by gp39 and IL-4. The mAbs 89-76 and 24-31 were most effective at inhibiting the induced B cell proliferation. The IC₅₀ (concentration of antibody necessary to inhibit B cell proliferation by 50 %) was approximately 1 µg/ml for 89-76 and approximately 1.25 µg/ml for 24-31.

Next, the ability of the mAbs to inhibit B cell differentiation, as measured by Ig production induced by anti-CD3 activated T cells and IL-2, was examined. Purified IgD⁺ human B cells were prepared by positive selection with FACS and then cultured with anti-CD3 activated human T cells (mitomycin C treated) and IL-2 for 6 days in the presence or absence of purified anti-gp39 monoclonal antibodies at dosages between 0 and 10 µg/ml. IgM, IgG and IgA production was assessed by ELISA on day 6. The results (shown below in Table 3) demonstrate that all six antibodies can inhibit T cell dependent B cell differentiation, as measured by IgM, IgG and IgA production. The IC₅₀ (concentration of antibody necessary to inhibit Ig production by 50%) was in the range of 1.0 µg/ml to below 0.1 µg/ml for the six mAbs, including the 24-31 and 89-76 antibodies.

Table 3

mAb	µg/ml	Production of Immunoglobulin		
		IgM	IgG	IgA
none	-	17,500	6710	4471
4D9-8	0.1	4813	2130	2819
	1.0	4394	2558	1519
	10.0	1081	389	396
4D9-9	0.1	3594	919	1731
	1.0	2659	1233	1606
	10.0	374	448	266
24-31	0.1	3863	981	344
	1.0	1287	314	185
	10.0	1120	596	23

Table 3 (continued)

mAb	$\mu\text{g/ml}$	Production of Immunoglobulin		
		IgM	IgG	IgA
24-43	0.1	6227	4132	432
	1.0	3193	2130	192
	10.0	7021	1232	1081
89-76	0.1	3783	1069	344
	1.0	2180	352	171
	10.0	818	551	19
89-79	0.1	9763	1924	3021
	1.0	2314	460	156
	10.0	183	135	434

To examine the effect of the anti-gp39 mAbs on T cell responses, the mAbs were included in standard mixed lymphocyte reactions (MLR). 300,000 human peripheral blood lymphocytes (responders = R) were cultured with 100,000 irradiated allogeneic peripheral blood lymphocytes (stimulators = S) in the presence or absence of anti-gp39 mAbs (10 $\mu\text{g/ml}$). Cultures were pulsed with 3H-thymidine on day 4, 5 or 6 and harvested 18 hours later. All six anti-human gp39 mAbs inhibited allo-specific responses as measured by MLR (see Figure 13 for a representative example, depicting inhibition of allo-specific responses when R and S are incubated in the presence of 24-31 or 89-76; a CTLA4-immunoglobulin fusion protein and an anti-CD28 mAb were used as positive controls).

To determine whether the six mAbs recognized distinct epitopes on the human gp39 molecule, crossblocking experiments were performed. Activated human PBLs were first blocked with each of the six mAbs (25 $\mu\text{g/ml}$ of unconjugated antibody). Cells were washed and then stained with 10 $\mu\text{g/ml}$ of biotin-conjugated antibody, followed by reaction with phytoerythrin conjugated avidin (PE-Av). The staining of the cells with PE-Av was analyzed by FACS. The results are shown below in Table 4.

Table 4

Blocking	Staining Antibody					
Ab	4D9-8	4D9-9	24-31	24-43	89-76	89-79
none	+++	+++	++++	++++	++++	++++
4D9-8	ND	-	++++	++++	+++	+++
4D9-9	+++	ND	+++	++++	+++	+++
24-31	+	+	ND	+++	++	++
24-43	+	+	+++	ND	++	+
89-76	+	+	+++	+++	ND	+++
89-79	+	++	+++	+++	+++	ND
The intensity of staining and the percentage of positive cells are represented by the + symbol (++++ = MI >200; +++ = MI >125; ++ = MI >50; + = MI >25; - = no staining above background). ND= not determined.						

All antibodies blocked the binding of CD40Ig to activated human PBLs. However, the data shown in Table 4 clearly demonstrate the failure of some antibodies to block the binding of other antibodies to activated human PBLs, suggesting that they recognize distinct epitopes on the human gp39 molecules.

The 89-76 and 24-31 hybridomas, producing the 89-76 and 24-31 antibodies, respectively, were deposited under the provisions of the Budapest Treaty with the American Type Culture Collection, Parkawn Drive, Rockville, Md., on September 2, 1994. The 89-76 hybridoma was assigned ATCC Accession Number HB 11713 and the 24-31 hybridoma was assigned ATCC Accession Number HB 11712. The 24-31 and 89-76 antibodies are of the IgG1 isotype.

Experiment 3- Antibodies directed against mouse gp39

In one embodiment of the invention, the gp39 antagonist is an anti-mouse gp39 monoclonal antibody, MR1. The following method was used to produce the MR1 monoclonal antibody, and may be used to generate other antibodies directed toward gp39.

Hamsters were immunized intraperitoneally with $5 \cdot 10^6$ activated T_H1 cells (d1.6) at weekly intervals for six weeks. When the serum titer against marine T_H1 was greater than about 1:10,000, cell fusions were performed with polyethylene glycol using immune hamster splenocytes and NS-1. Supernatant from wells containing growing hybridomas were screened by flow cytometry on resting and activated T_H1 . One particular hybridoma, which produced a Mab that selectively recognized activated T_H1 was further tested and subcloned to derive MR1. MR1 was produced in ascites and purified by ion exchange HPLC. A hybridoma MR1 has been deposited with the American Type Culture Collection and assigned Accession Number HB11048.

Claims**1. Use of:**

- (a) a cell which presents antigen to a T cell and has a ligand on a cell surface which interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and
- (b) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand with the receptor;

for the preparation of a medicament for inducing antigen-specific T cell tolerance *in vivo*.

2. Use of

- (a) a cell which presents antigen to a T cell and has a ligand which interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function;
- (b) an antigen which is capable of association with the cell which presents antigen to a T cell; and
- (c) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand with the receptor,

for the preparation of a pharmaceutical composition for inducing antigen-specific T cell tolerance *in vivo*.

3. A method for inducing antigen-specific T cell tolerance *in vitro* comprising contacting a T cell with:

- (a) a cell which presents antigen to a T cell and has a ligand which interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and
- (b) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand with the receptor.

4. A method for inducing antigen-specific T cell tolerance *in vitro* comprising contacting a T cell with:

- (a) a cell which presents antigen to a T cell and has a ligand which interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function;
- (b) an antigen which is capable of association with the cell which present antigen to a T cell; and
- (c) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand with the receptor.

5. The use or method of any one of claims 1 to 4, wherein the receptor on the surface of a T cell which mediates contact-dependent effector function is gp39.**6. The use or method of claim 5, wherein the antagonist is an anti-gp39 antibody.****7. The use or method of claim 6, wherein the anti-gp39 antibody is an anti-human gp39 antibody.****8. The use or method of claim 6 or 7, wherein the anti-gp39 antibody is a monoclonal antibody.**

9. The use of method of claim 8, wherein the anti-gp39 antibody is monoclonal antibody 24-31 (ATCC No. HB 11712) or 89-76 (ATCC No. HB 11713).
10. The use or method of claim 7, wherein the anti-gp39 antibody is a chimeric monoclonal antibody.
11. The use or method of claim 7 or 10, wherein the anti-gp39 antibody is a humanized monoclonal antibody.
12. The use or method of claim 5, wherein the antagonist is a soluble form of CD40.
13. The use or method of claim 12, wherein the soluble form of CD40 is a fusion protein.
14. The use or method of any one of claims 1 to 13, wherein the cell is a lymphoid cell.
15. The use or method of claim 14, wherein the lymphoid cell is a B cell.
16. The use or method of claim 15, wherein the B cell is a resting B cell.
17. The use of method of claim 15 or 16, wherein the cell is an allogeneic B cell.
18. The use or method of claim 15 or 17, wherein the B cell is contacted with antigen prior to contacting with the T cell.
19. The use or method of any one of claims 1 to 18, wherein the cell is from peripheral blood or allogeneic bone marrow.
20. The use or method of any one of claims 1 to 19, wherein the antigen is a protein.
21. The use or method of claim 20, wherein the protein is an autoantigen, an alloantigen or an allergen.
22. Use of a gp39 antagonist for the preparation of a medicament for inducing antigen-specific T cell tolerance *in vivo* in a subject exposed to such antigen.
23. Use of a gp39 antagonist for the preparation of a medicament for inducing antigen-specific tolerance in a subject, wherein such gp39 antagonist induces antigen-specific T cell tolerance by interacting with a cell which presents antigen to a T cell and which has a ligand on a cell surface which interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function.
24. Use of a gp39 antagonist for the preparation of a medicament for inducing antigen-specific T cell tolerance *in vivo* wherein such gp39 antagonist induces T cell tolerance by interacting with:
 - a cell which is capable of presenting an antigen to a T cell and which comprises a ligand which interacts with a receptor on the surface of a T cell which mediates contact-dependent helper effector function; and
 - an antigen which is capable of associating with the cell which presents antigen to the T cell.
25. The use of any of Claims 22, 23 or 24, wherein the gp39 antagonist is an anti-gp39 antibody or a soluble CD40 fusion protein.
26. The use of Claim 25, wherein the anti-gp39 antibody is an anti-human gp39 monoclonal antibody.
27. The use of Claim 26, wherein said monoclonal antibody is a humanized or chimeric monoclonal antibody.
28. The use of Claims 23 or 24, wherein the antigen presenting cell is a CD40 expressing cell.
29. The use of Claim 28, wherein such cells comprise lymphoid cells such as B lymphocytes; "professional" antigen-presenting cells such as monocytes, dendritic cells and Langerhan cells; and other cells which present antigen to immune cells comprising Keratinocytes, endothelial cells, astrocytes, fibroblasts, or oligodendrocytes.
30. The use of any of Claims 22, 23 or 24, wherein the antigen is an autoantigen, alloantigen or allergen.

Patentansprüche

1. Verwendung

- 5 (a) einer Zelle, die einer T-Zelle Antigen präsentiert und einen Liganden auf einer Zelloberfläche aufweist, der mit einem Rezeptor auf der Oberfläche der T-Zelle wechselwirkt, welcher eine kontaktabhängige Helfer-Effektor-Funktion vermittelt; und
(b) eines Antagonisten des Rezeptors auf der Oberfläche der T-Zelle, welcher die Wechselwirkung des Liganden mit dem Rezeptor hemmt;

10 für die Herstellung eines Medikaments zur Induzierung einer Antigen-spezifischen T-Zellen-Toleranz in vivo.

2. Verwendung

- 15 (a) einer Zelle, die einer T-Zelle Antigen präsentiert und einen Liganden aufweist, der mit einem Rezeptor auf der Oberfläche der T-Zelle wechselwirkt, welcher eine kontaktabhängige Helfer-Effektor-Funktion vermittelt;
(b) eines Antigens, das zur Assoziierung mit der Zelle, die einer T-Zelle Antigen präsentiert, in der Lage ist; und
(c) eines Antagonisten des Rezeptors auf der Oberfläche der T-Zelle, welcher die Wechselwirkung des Liganden mit dem Rezeptor hemmt;

20 für die Herstellung einer pharmazeutischen Zusammensetzung zur Induzierung einer Antigen-spezifischen T-Zellen-Toleranz in vivo.

- 25 3. Verfahren zur Induzierung einer Antigen-spezifischen T-Zellen-Toleranz in vitro, umfassend das Inkontaktbringen einer T-Zelle mit:

- (a) einer Zelle, die einer T-Zelle Antigen präsentiert und einen Liganden aufweist, der mit einem Rezeptor auf der Oberfläche der T-Zelle wechselwirkt, welcher eine kontaktabhängige Helfer-Effektor-Funktion vermittelt; und
30 (b) einem Antagonisten des Rezeptors auf der Oberfläche der T-Zelle, welcher die Wechselwirkung des Liganden mit dem Rezeptor hemmt.

- 35 4. Verfahren zur Induzierung einer Antigen-spezifischen T-Zellen-Toleranz in vitro, umfassend das Inkontaktbringen einer T-Zelle mit:

- (a) einer Zelle, die einer T-Zelle Antigen präsentiert und einen Liganden aufweist, der mit einem Rezeptor auf der Oberfläche der T-Zelle wechselwirkt, welcher eine kontaktabhängige Helfer-Effektor-Funktion vermittelt;
(b) einem Antigen, das zur Assoziierung mit der Zelle, die einer T-Zelle Antigen präsentiert, in der Lage ist; und
40 (c) einem Antagonisten des Rezeptors auf der Oberfläche der T-Zelle, welcher die Wechselwirkung des Liganden mit dem Rezeptor hemmt.

5. Verwendung oder Verfahren nach irgendeinem der Ansprüche 1 bis 4, bei der bzw. dem der Rezeptor auf der Oberfläche einer T-Zelle, welcher die kontaktabhängige Effektor-Funktion vermittelt, gp39 ist.

- 45 6. Verwendung oder Verfahren nach Anspruch 5, bei der bzw. dem der Antagonist ein Anti-gp39-Antikörper ist.

7. Verwendung oder Verfahren nach Anspruch 6, bei der bzw. dem der Anti-gp39-Antikörper ein Anti-Human-gp39-Antikörper ist.

- 50 8. Verwendung oder Verfahren nach Anspruch 6 oder 7, bei der bzw. dem der Anti-gp39-Antikörper ein monoklonaler Antikörper ist.

9. Verwendung oder Verfahren nach Anspruch 8, bei der bzw. dem der Anti-gp39-Antikörper ein monoklonaler Antikörper 24-31 (ATCC Nr. HB 11712) oder 89-76 (ATCC Nr. HB 11713) ist.

- 55 10. Verwendung oder Verfahren nach Anspruch 7, bei der bzw. dem der Anti-gp39-Antikörper ein chimärer monoklonaler Antikörper ist.

11. Verwendung oder Verfahren nach Anspruch 7 oder 10, bei der bzw. dem der Anti-gp39-Antikörper ein humanisierter monoklonaler Antikörper ist.
12. Verwendung oder Verfahren nach Anspruch 5, bei der bzw. dem der Antagonist eine lösliche Form von CD40 ist.
13. Verwendung oder Verfahren nach Anspruch 12, bei der bzw. dem die lösliche Form von CD40 ein Fusionsprotein ist.
14. Verwendung oder Verfahren nach irgendeinem der Ansprüche 1 bis 13, bei der bzw. dem die Zelle eine Lymphzelle ist.
15. Verwendung oder Verfahren nach Anspruch 14, bei der bzw. dem die Lymphzelle eine B-Zelle ist.
16. Verwendung oder Verfahren nach Anspruch 15, bei der bzw. dem die B-Zelle eine ruhende B-Zelle ist.
17. Verwendung nach Anspruch 15 oder 16, bei der bzw. dem die Zelle eine allogene B-Zelle ist.
18. Verwendung oder Verfahren nach Anspruch 15 oder 17, bei der bzw. dem die B-Zelle vor dem Kontakt mit der T-Zelle mit Antigen in Kontakt gebracht wird.
19. Verwendung oder Verfahren nach irgendeinem der Ansprüche 1 bis 18, bei der bzw. dem die Zelle aus peripherem Blut oder allogenen Knochenmark stammt.
20. Verwendung oder Verfahren nach irgendeinem der Ansprüche 1 bis 19, bei der bzw. dem das Antigen ein Protein ist.
21. Verwendung oder Verfahren nach Anspruch 20, bei der bzw. dem das Protein ein Autoantigen, ein Alloantigen oder ein Allergen ist.
22. Verwendung eines gp39-Antagonisten für die Herstellung eines Medikamentes zum Induzieren einer Antigen-spezifischen T-Zellen-Toleranz in vivo in einem Subjekt, das einem derartigen Antigen ausgesetzt ist.
23. Verwendung eines gp-39-Antagonisten für die Herstellung eines Medikamentes zum Induzieren einer Antigen-spezifischen Toleranz in einem Subjekt, wobei ein derartiger gp39-Antagonist eine Antigen-spezifische T-Zellen-Toleranz induziert, indem er mit einer Zelle wechselwirkt, die einer T-Zelle ein Antigen präsentiert und die einen Liganden auf einer Zelloberfläche aufweist, welcher mit einem Rezeptor auf der Oberfläche der T-Zelle wechselwirkt, welcher eine kontaktabhängige Helfer-Effektor-Funktion vermittelt.
24. Verwendung eines gp-39-Antagonisten für die Herstellung eines Medikamentes zum Induzieren einer Antigen-spezifischen T-Zellen-Toleranz in vivo, wobei ein derartiger gp39-Antagonist eine Antigen-spezifische T-Zellen-Toleranz induziert, indem er wechselwirkt mit:

einer Zelle, die einer T-Zelle ein Antigen präsentieren kann und die einen Liganden aufweist, welcher mit einem Rezeptor auf der Oberfläche einer T-Zelle wechselwirkt, welcher eine kontaktabhängige Helfer-Effektor-Funktion vermittelt; und

einem Antigen, das in der Lage ist, mit der Zelle zu assoziieren, die der T-Zelle Antigen präsentiert.
25. Verwendung nach irgendeinem der Ansprüche 22, 23 oder 24, bei welcher der gp39-Antagonist ein Anti-gp39-Antikörper oder ein lösliches CD40-Fusionsprotein ist.
26. Verwendung nach Anspruch 25, bei welcher der Anti-gp39-Antikörper ein monoklonaler Anti-Human-gp39-Antikörper ist.
27. Verwendung nach Anspruch 26, bei welcher der monoklonale Antikörper ein monoklonaler humanisierter oder chimärer Antikörper ist.
28. Verwendung nach Anspruch 23 oder 24, bei welcher die Antigen-präsentierende Zelle eine CD40 exprimierende Zelle ist.

29. Verwendung nach Anspruch 28, bei welcher derartige Zellen Lymphzellen, wie beispielsweise B-Lymphozyten; "professionelle" Antigen-präsentierende Zellen, wie beispielsweise Monozyten, dendritische Zellen und Langerhans-Zellen; und andere Zellen umfassen, die Immunzellen Antigen präsentieren und Keratinozyten, Endothelzellen, Astrozyten, Fibroblasten oder Oligodendrozyten umfassen.

30. Verwendung nach Irgendeinem der Ansprüche 22, 23 oder 24, bei welcher das Antigen ein Autoantigen, Alloantigen oder Allergen ist.

Revendications

1. Utilisation :

- (a) d'une cellule qui présente un antigène à un lymphocyte T et qui possède un ligand sur une surface cellulaire qui interagit avec un récepteur sur la surface du lymphocyte T, assurant la médiation de la fonction d'effecteur auxiliaire sous la dépendance d'un contact ; et
- (b) d'un antagoniste du récepteur sur la surface du lymphocyte T, qui inhibe l'interaction du ligand avec le récepteur ;

pour la préparation d'un médicament destiné à induire une tolérance des lymphocytes T spécifique de l'antigène in vivo.

2. Utilisation

- (a) d'une cellule qui présente un antigène à un lymphocyte T et qui possède un ligand qui interagit avec un récepteur sur la surface du lymphocyte T, assurant la médiation de la fonction d'effecteur auxiliaire sous la dépendance d'un contact ;
- (b) d'un antigène qui est capable de s'associer à la cellule qui présente l'antigène à un lymphocyte T ; et
- (c) d'un antagoniste du récepteur sur la surface du lymphocyte T, qui inhibe l'interaction du ligand avec le récepteur,

pour la préparation d'une composition pharmaceutique destinée à induire une tolérance des lymphocytes T spécifique de l'antigène in vivo.

3. Procédé pour induire une tolérance de lymphocytes T spécifique d'un antigène in vitro, comprenant la mise en contact d'un lymphocyte T avec :

- (a) une cellule qui présente un antigène à un lymphocyte T et qui possède un ligand qui interagit avec un récepteur sur la surface du lymphocyte T, assurant la médiation de la fonction d'effecteur auxiliaire sous la dépendance d'un contact ; et
- (b) un antagoniste du récepteur sur la surface du lymphocyte T, qui inhibe l'interaction du ligand avec le récepteur.

4. Procédé pour induire une tolérance de lymphocytes T spécifique d'un antigène in vitro, comprenant la mise en contact d'un lymphocyte T avec :

- (a) une cellule qui présente un antigène à un lymphocyte T et qui possède un ligand qui interagit avec un récepteur sur la surface du lymphocyte T, assurant la médiation de la fonction d'effecteur auxiliaire sous la dépendance d'un contact ;
- (b) un antigène qui est capable de s'associer à la cellule qui présente l'antigène à un lymphocyte T ;
- (c) un antagoniste du récepteur sur la surface du lymphocyte T, qui inhibe l'interaction du ligand avec le récepteur.

5. Utilisation ou procédé suivant l'une quelconque des revendications 1 à 4, dans lequel le récepteur sur la surface d'un lymphocyte T qui assure la médiation de la fonction d'effecteur sous la dépendance d'un contact est le récepteur gp39.

6. Utilisation ou procédé suivant la revendication 5, dans lequel l'antagoniste est un anticorps anti-gp39.

7. Utilisation ou procédé suivant la revendication 6, dans lequel l'anticorps anti-gp39 est un anti-corps anti-gp39 humain.
- 5 8. Utilisation ou procédé suivant la revendication 6 ou 7, dans lequel l'anticorps anti-gp39 est un anticorps monoclonal.
9. Utilisation ou procédé suivant la revendication 8, dans lequel l'anticorps anti-gp39 est l'anticorps monoclonal 24-31 (ATCC N° HB 11712) ou 89-76 (ATCC N° HB 11713).
- 10 10. Utilisation ou procédé suivant la revendication 7, dans lequel l'anticorps anti-gp39 est un anti-corps monoclonal chimère.
11. Utilisation ou procédé suivant la revendication 7 ou 10, dans lequel l'anticorps anti-gp39 est un anticorps monoclonal humanisé.
- 15 12. Utilisation ou procédé suivant la revendication 5, dans lequel l'antagoniste est une forme soluble de CD40.
13. Utilisation ou procédé suivant la revendication 12, dans lequel la forme soluble de CD40 est une protéine de fusion.
- 20 14. Utilisation ou procédé suivant l'une quelconque des revendications 1 à 13, dans lequel la cellule est une cellule lymphoïde.
15. Utilisation ou procédé suivant la revendication 14, dans lequel la cellule lymphoïde est un lymphocyte B.
- 25 16. Utilisation ou procédé suivant la revendication 15, dans lequel le lymphocyte B est un lymphocyte B quiescent.
17. Utilisation ou procédé suivant la revendication 15 ou 16, dans lequel la cellule est un lymphocyte B allogénique.
- 30 18. Utilisation ou procédé suivant la revendication 15 ou 17, dans lequel le lymphocyte B est mis en contact avec l'antigène avant la mise en contact avec le lymphocyte T.
19. Utilisation ou procédé suivant l'une quelconque des revendications 1 à 18, dans lequel la cellule provient de sang périphérique ou de moelle osseuse allogénique.
- 35 20. Utilisation ou procédé suivant l'une quelconque des revendications 1 à 19, dans lequel l'antigène est une protéine.
21. Utilisation ou procédé suivant la revendication 20, dans lequel la protéine est un auto-antigène, un allo-antigène ou un allergène.
- 40 22. Utilisation d'un antagoniste de gp39 pour la préparation d'un médicament destiné à induire une tolérance de lymphocytes T spécifique d'un antigène in vivo chez un sujet exposé à un tel antigène.
23. Utilisation d'un antagoniste de gp39 pour la préparation d'un médicament destiné à induire une tolérance spécifique d'un antigène chez un sujet, dans laquelle cet antagoniste de gp39 induit une tolérance de lymphocytes T spécifique d'un antigène en interagissant avec une cellule qui présente l'antigène à un lymphocyte T et qui possède un ligand sur une surface cellulaire qui interagit avec un récepteur sur la surface du lymphocyte T qui assure la médiation de la fonction d'effecteur auxiliaire sous la dépendance d'un contact.
- 45 24. Utilisation d'un antagoniste de gp39 pour la préparation d'un médicament destiné à induire une tolérance de lymphocytes T spécifique d'un antigène in vivo, dans laquelle cet antagoniste de gp39 induit une tolérance de lymphocytes T en interagissant avec :

une cellule qui est capable de présenter un antigène à un lymphocyte T et qui comprend un ligand qui interagit avec un récepteur sur la surface d'un lymphocyte T qui assure la médiation de la fonction d'effecteur auxiliaire sous la dépendance d'un contact ; et

un antigène qui est capable de s'associer à la cellule qui présente l'antigène au lymphocyte T.
- 60 25. Utilisation suivant l'une quelconque des revendications 22, 23 et 24, dans laquelle l'antagoniste de gp39 est un

anticorps anti-gp39 ou une protéine de fusion CD40 soluble.

26. Utilisation suivant la revendication 25, dans laquelle l'anticorps anti-gp39 est un anticorps monoclonal anti-gp39 humain.

5

27. Utilisation suivant la revendication 26, dans laquelle l'anticorps monoclonal est un anticorps monoclonal humanisé ou chimère.

28. Utilisation suivant la revendication 23 ou 24, dans laquelle la cellule présentatrice d'antigène est une cellule exprimant CD40.

10

29. Utilisation suivant la revendication 28, dans laquelle de telles cellules comprennent des cellules lymphoïdes telles que des lymphocytes B ; des cellules "professionnelles" présentatrices d'antigène telles que des monocytes, des cellules dendritiques et des cellules de Langerhans ; et d'autres cellules qui présentent l'antigène à des cellules immunitaires, comprenant des kératinocytes, des cellules endothéliales, des astrocytes, des fibroblastes ou des oligodendrocytes.

15

30. Utilisation suivant l'une quelconque des revendications 22, 23 et 24, dans laquelle l'antigène est un auto-antigène, un allo-antigène ou un allergène.

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A




FIG. 4B




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10B




FIG. 10C




FIG. IIA




FIG. IIB




FIG. 12




FIG. 13

